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ABSTRACT 
 
Each year, malaria claims approximately half a million lives while infecting hundreds of millions of 
people worldwide. Plasmodium falciparum (Pf), the primary causative agent of human malaria, harbors 
an essential organelle known as the apicoplast. While the putative metabolic pathways within this 
organelle have been largely elucidated, proteins required for its maintenance remain to be determined. 
To address this, we have genetically engineered the PfMev parasite line, to which exogenous 
supplementation of Mevalonate, a precursor metabolite for mammalian isoprenoid biosynthesis, 
enables the survival of parasites that have lost the apicoplast. Using this metabolic bypass line, we 
have knocked out various proteins related to the SUF pathway, and determined that SufS and MnmA, 
two sulfur-utilizing proteins, are required for maintaining the apicoplast. To further explore proteins 
involved in apicoplast maintenance, we have demonstrated the capability of both the CLD system and 
TetR-DOZI system to conditionally knock down PyrKII, a protein that we have shown to be required 
for maintaining the apicoplast. These results on PyrKII pave the way for our plan of probing the 
resultant changes within the nuclear and plastidial transcriptome.  
In addition, due to the sustained recurrence of drug resistance in Plasmodium parasites, there is 
a constant need for the search and development of novel effective antimalarials. One promising 
candidate, triclosan, exhibits anti-plasmodial activity at the micro-molar range. With the goal of 
discovering a triclosan analog with substantially amplified antiparasitic activity, we have screened seven 
triclosan analogs for their antiparasitic activity against blood stage Pf. Through conducting this screen, 
we have confirmed the potency of a compound, designated herein as djm-11-03A, and seek to identify 
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CHAPTER 1: Introduction to malaria  
Malaria as a public health burden  
Malaria is an ancient disease that has plagued mankind for over 4,000 years. Each year, the deadly 
disease infects hundreds of millions of people worldwide, endangering nearly half of the world’s 
population [1]. In 2016, globally, there were approximately 216 million reported cases of malaria 
infections and 445,000 deaths. Among the reported cases, 90% of the infections and 91% of the deaths 
occurred in Africa, while the rest of the incidences were scattered throughout Southeast Asia, Europe, 
and the Americas [1]. In addition to the considerable death toll incurred, the disease constitutes a 
significant source of financial strain on the government of the endemic countries and those who 
pledge to help eradicate the disease, collectively. In fact, in 2016 alone, about 2.7 billion dollars were 
spent on the global control/elimination of malaria [1], which included measures such as vector control, 
diagnosis, and treatment [1]. As such, malaria is not only a life-threatening disease, but also a significant 
economic burden. 
Human malaria is caused by five species of Plasmodium parasites. In particular, Plasmodium 
falciparum (Pf), the most deadly among the five, is most prevalent in West Africa and accounts for the 
majority of the malaria cases [1], while Plasmodium vivax (Pv), the runner-up, primarily affects other 
countries outside of Sub-Saharan Africa [1].  
 
The Plasmodium mosquito stage  
The Plasmodium parasite has a complex life cycle (reviewed in [2], [3], and [4]) that involves two hosts, 
the human and the female Anopheles mosquito, and three developmental stages – the mosquito stage, 
the asexual liver stage (ALS), and the asexual blood stage (ABS). Shown below is a summary of the 
general characteristics of the parasite throughout the various stages of its complete life cycle (Table 





the parasitized RBCs from that individual, thereby initiating the 17-day sporogonic cycle. Importantly, 
actual successful infection of the mosquito by the parasite requires the sexual reproduction of the 
parasites within the mosquito. Specifically, upon arrival inside the midgut of the mosquito, the male 
and female gametocytes (the sexual form of the parasite) exit the RBCs and differentiate into gametes 
of the respective sex. A male gamete penetrates and fuses with a female gamete, generating a fertilized 
female gamete, also known as a zygote, the only diploid form of the Plasmodium parasite (during all 
other stages of its life cycle, the parasite is haploid). These zygotes, through physical elongation and 
the acquisition of motility, develop into what are called ookinetes, which then invade and lodge under 
the basal lamina of the mosquito midgut, where they subsequently develop into oocysts. In the final 
phase of the Plasmodium life cycle within the mosquito, the oocysts rupture and release sporozoites in 
a process known as sporogony. These free sporozoites then make their way from the midgut to the 
salivary glands of the mosquito.  
 
The Plasmodium asexual liver stage (ALS) 
Plasmodium asexual reproduction during the ALS is largely analogous to that of the ABS. In addition, 
since the work presented herein focuses on the ABS, the ALS is described only in brief. When taking 
a blood meal from a human, a malaria-infected mosquito inoculates sporozoites from its salivary 
glands into the bitten human, thereby initiating the ALS, which in Pf takes approximately 10 days to 
complete. After their injection through the human dermis, the sporozoites travel within the 
bloodstream to reach the liver, where they infect liver cells (LCs) and mature into the form of the 
parasite known as a schizont, each of which contains multiple daughter merozoites. Upon sufficient 
parasitic development, the LC ruptures to release 1,000s of daughter merozoites, which enter the 
bloodstream once again to invade RBCs. Upon successful invasion of a RBC, an encapsulating 





vacuole that subsequent parasite growth and development during the ABS occurs.  
 
The Plasmodium asexual blood stage (ABS)  
The ABS, which is responsible for the clinical manifestations of malaria, consists of four 
developmental stages. During a mere 2-minute window of this 2-day life cycle, free parasites, i.e., 
merozoites, are in the process of invading RBCs (Figure 1.1A). The successful invasion of a RBC 
followed by the establishment of the merozoite(s) therein launches the ring-stage, during which the 
parasite body takes on a characteristic ring shape (Figure 1.1B) that gradually enlarges during growth. 
Throughout this stage of its life cycle, the parasite starts to ingest the host cell hemoglobin, which gets 
hydrolyzed to its protein component (amino acids) and its non-protein component (iron-containing 
heme). The amino acids are taken up as nutrition, while the heme can produce reactive oxygen species 
that are toxic to the parasite. As the parasite grows, it morphologically transitions from the ring shape 
to an ameboid shape, which marks the start of the trophozoite-stage (Figure 1.1C). At the 
trophozoite-stage, the reactive oxygen species derived from hemoglobin ingestion have accumulated 
enough to constitute a substantial source of oxidative stress. In order to overcome this toxicity, the 
parasite generates a hemozoin crystal consisting of heme organized in order to limit exposure of the 
iron atoms. Continuing on the developmental cycle, division of parasite organelles and genomic 
replication occurs. Now, although each Pf parasite harbors numerous organelles, only three contain 
their own genomes – the nucleus, apicoplast, and mitochondrion, which are collectively referred to as 
the “organellar trio” hereafter. Notably, each Pf parasite carries a single apicoplast and mitochondrion, 
and these two organelles remain in close proximity to each other throughout the ABS [5]. Upon 
sufficient development under the trophozoite-stage, the parasite undergoes a process known as 
schizogony. During this intricately orchestrated process, each member of the parental cell organellar 





such that each resulting daughter cell, i.e., merozoite, is able to acquire its own organellar trio [5], 
yielding a schizont-stage parasite that contains 16 – 32 daughter merozoites (Figure 1.1D). Notably, 
at the schizont-stage, sufficient amount of heme has been incorporated into the hemozoin crystal so 
as to confer a paramagnetic property that is particularly strong at this stage of the parasite life cycle. 
From an experimental standpoint, such a distinguishing feature conveniently enables the isolation of 
schizont-stage parasites from a mixed-stage culture via purification under a strong magnetic field (see 
the MATERIALS AND METHODS section of CHAPTER 3 for more details). During the final 
phase of schizogony, the daughter merozoites within an individual schizont can undergo one of two 
fates. As the first option, the merozoites rupture the RBC membrane and thereupon get released into 
the bloodstream to invade new RBCs, thus launching another cycle of the ABS within the same human 
host. As an alternative to perpetuating the ABS, the merozoites can differentiate into gametocytes, 
which can be ingested by a mosquito during a blood meal, thereby initiating a new round of 

























Table 1.1. Summary of general characteristics of Plasmodium falciparum. The six characteristics 
shown are: (1) physical location, (2) mode of reproduction, (3) ploidy, (4) associated physical form(s), 
(5) whether the parasites are pathologic to the infected human host, and (6) the approximate duration 
to achieve completion of the particular life cycle within Pf. The asexual and sexual forms of the parasite, 





Ploidy Associated physical forms Pathologic time 
Mosquito 
(saliva) 
Asexual Haploid  • Sporozoite  No N/A 
Mosquito 
(midgut) 
Sexual Haploid* • Gametocyte  
• Gamete  
• Zygote  
• Ookinete  
• Oocyst  
• Sporozoite  
No 17 d 
Human 
(LC) 
Asexual Haploid • Merozoite  
• Ring  
• Trophozoite 
• Schizont 





Haploid • Merozoite  





Yes 48 h 
15 d 
 
*The Plasmodium parasite remains haploid throughout all stages of its life cycle, with one exception: 







Figure 1.1. A simplified depiction of the Pf ABS life cycle. (A) A merozoite is a free parasite 
attempting to invade a RBC. (B) Once established within a RBC, the merozoite develops and enlarges 
into a ring, which has a characteristic ring shape. (C) A ring further develops into a trophozoite, which 
is ameboid and has a hemozoin crystal resulting from the ingestion of RBC hemoglobin. (D) A 
trophozoite undergoes a division known as schizogony, giving rise to a single schizont that contains 
16 – 32 daughter merozoites. Eventually, the parasitized RBC ruptures, releasing the daughter 
merozoites into the bloodstream and starting the ABS anew. The various color-coded components 
are indicated for the trophozoite-stage.  
 
The Plasmodium apicoplast 
Plasmodium spp. are among the ~5,000 species of parasites that belong to the phylum Apicomplexa. 
Although these obligate intracellular parasites are minute in size, they pose a formidable threat to 
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responsible for babesiosis and theileriosis, respectively, both common diseases of livestock, while 
Toxoplasma gondii (Tg) and Plasmodium spp. are the respective causative agents of the human diseases 
toxoplasmosis and malaria. Now, despite the variety of genera and associated diseases attributed to 
this phylum, apicomplexans have been thought to possess two common defining physical features – 
(1) the apical complex, an anterior structure comprised of individual secretory organelles (micronemes, 
rhoptries, and dense granules) that collectively enable the parasite to invade the host cell and establish 
itself therein, and (2) the apicoplast, a relict plastid containing a well-conserved 35 k.b. circular genome. 
That being said, the apparent absence of the apicoplast has been demonstrated in certain genera within 
the phylum, including Cryptosporidium spp. [6] and the related Gregarina spp. [7], and could be potentially 
attributed to the early evolutionary divergence of these species from other members of the phylum 
and loss of the organelle. Notwithstanding these exceptions, however, the apicoplast is not only 
present within Plasmodium spp. but also houses metabolic pathways requisite to the development 
and/or survival of the parasite during both the ABS [8] and the ALS [9, 10].  
The apoplast is thought to be evolutionarily derived from two sequential endosymbiotic events 
(reviewed in [11] and [12]) (Figure 1.2). In the first, i.e., primary endosymbiosis, a photosynthetic 
cyanobacterium was engulfed and retained by a eukaryote, giving rise to a red alga circa 1.3 Gya. At 
this stage, the endosymbiont would have functioned as a two-membrane chloroplast. Thereafter, 
around 800 Mya, the red alga was presumably engulfed and retained by another heterotrophic 
eukaryote, giving rise to a group of organisms collectively termed Chromalveolates, to which 
apicomplexans belong. The plasma membrane of the algal cell collapsed onto its chloroplast, adding 
a third membrane to the organelle, while a fourth vacuolar membrane was added during the 
engulfment of the algal cell by the second heterotrophic eukaryote. Over the course of evolutionary 
time, this remnant chloroplast retained its organellar genome, but lost redundant genes and those 





substantial implications for the parasite in terms of the targeting of nuclear-encoded apicoplast-
localized proteins (discussed below) and their traversal across the quadruple plastidial membrane (not 
covered herein).  
As mentioned above, each member of the organellar trio has its individual genome. More 
specifically, Pf contains a nuclear genome, which contains 14 chromosomes and 5,268 protein-
encoding genes [13], as well as two extra-chromosomal DNA elements – a 6 k.b. mitochondrial 
genome and a 35 k.b. apicoplast genome, both of which are maternally inherited based on evidence 
from Plasmodium gallinaceum [14]. The Pf apicoplast genome, in particular, consists of a circular sequence 
of 38,682 nucleotides that almost exclusively encode biomolecules involved in gene expression [15], 
such as rRNAs, tRNAs, and ribosomal proteins [15]. Such diminutive size and streamlined proteome 
of this plastid genome are presumably evolutionary consequences of the transfer of genes from the 
endosymbiont to the host cell nucleus, as a means to minimize the chances of accumulating deleterious 
genetic mutations. Now, because the apicoplast genome has a limited repertoire of encoded proteins, 
specific nuclear-encoded proteins must be imported into the apicoplast to fulfill their metabolic 
functions therein. In that regard, as there are several organelles within the parasite, such proteins must 
be specifically targeted to the plastid, a cardinal task accredited to the N-terminal bipartite pre-
sequence present on these nuclear-encoded proteins [16] (for a more detailed discussion of apicoplast-
targeting of nuclear-encoded proteins, see the INTRODUCTION section of CHAPTER 4). 
Importantly, the Pf bipartite pre-sequence consists of a signal peptide and a transit peptide [16], and 
Pf transit peptides can be distinguished from the mature proteins with respect to the prevalence of 
particular amino acids [17]. As such, these distinguishing features conveniently enabled the creation 
of a bioinformatic tool known as Plasmodium falciparum apicoplast-targeted proteins (PlasmoAP), which 
utilizes a set of criteria based on amino acid sequence to identify putative bipartite pre-sequences, and 





[13], 466 were predicted to be targeted to the apicoplast by PlasmoAP [17]. This finding not only 
supported the notion that the organelle is reliant on specific nuclear-encoded proteins to carry out its 
function, but also facilitated the construction of the putative metabolic pathways within the organelle. 
All told, four major metabolic pathways are known to be present within the apicoplast – (1) the sulfur 
utilization factors (SUF) pathway of [Fe-S] cluster biosynthesis, (2) the methyl-erythritol phosphate 
(MEP) pathway of isoprenoid biosynthesis, (3) the type II fatty acid synthesis (FAS-II) pathway, and 
(4) the heme biosynthesis pathway.  
 
Figure 1.2. Secondary endosymbiotic origin of the apicoplast. During primary endosymbiosis 
circa 1.3 Gya, a cyanobacterium was engulfed and retained by a heterotrophic eukaryote, giving rise 
to a red alga cell containing a two-membrane chloroplast. During secondary endosymbiosis circa 800 
Mya, the red alga was engulfed and retained in a phagotrophic vacuole of a second heterotrophic 
eukaryote, giving rise to the group of organisms called Chromalveolates, to which apicomplexans 
belong. From inside out, the three innermost membranes of the apicoplast were derived from the two 
membranes of the chloroplast surrounded by the red algal plasma membrane, and the fourth 
membrane of the apicoplast was derived from the phagotrophic vacuole of the second eukaryote.  
Red alga:
Cyanobacterium:
Primary endosymbiosis (~1.3 Gya)
Chromalveolates:
Secondary endosymbiosis (~800 Mya)
Plasma membrane 
Phagotrophic vacuole  
From eukaryote #1
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Thesis rationale  
Although the putative metabolic pathways within the Pf apicoplast have been largely elucidated, the 
identity of specific apicoplast proteins that are required for maintaining this organelle, as well as the 
means by which these proteins do so, remain to be determined. As one would surmise, the reasonable 
method of unveiling the function of a protein is to alter its expression and subsequently investigate 
the aftermath of such tweaking at the genomic, transcriptomic, proteomic, or cellular/phenotypic level. 
However, because the apicoplast is an organelle that is essential to the survival of Pf, direct genetic 
deletion or knock-down of any protein that is required for maintaining this organelle would 
automatically result in the death of the parasite, necessitating the development of novel molecular 
tools that keep the parasite alive despite the loss of essential parasitic proteins. To that end, 
CHAPTER 2 showcases our genetically engineered PfMev line, which allows us to study essential 
parasite proteins under Mevalonate supplementation. Using this metabolic bypass line, we have 
examined proteins involved in the SUF pathway of [Fe-S] cluster biosynthesis with respect to their 
requirement for parasite survival as well as apicoplast maintenance during the ABS. To further explore 
proteins involved in apicoplast maintenance, we demonstrate, in CHAPTER 4, the capability of both 
the CLD system and TetR-DOZI system to conditionally knock down PyrKII, a protein that we have 
shown to be required for maintaining the apicoplast. Importantly, these results on PyrKII pave the 
way for our subsequent experimental approach to probe the resultant changes within the nuclear and 
plastidial transcriptome.  
Finally, since quinine ushered in the era of synthetic antimalarial drugs in the 1630s, there has 
been a sustained recurrence of drug resistance in Plasmodium parasites. As one would expect, these 
resistant parasite strains necessitate the search and development of novel effective antimalarials. 
Among the wide range of chemicals screened by various studies, one promising candidate is triclosan, 





numerous studies have examined a variety of triclosan analogs, with the hope of discovering an analog 
with substantially amplified antiparasitic activity. With the same goal in mind, we have, in CHAPTER 
3, screened seven triclosan analogs for their antiparasitic activity against ABS Pf. Among the examined 
analogs, we have confirmed the potency of a compound designated herein as djm-11-03A, which was 
found to be the most potent among the seven. Our next step is to induce drug resistance in ABS Pf 
using this analog in order to uncover the genetic determinants of resistance against this compound. 
This approach should identify the molecular targets of the compound within the parasite, and thus, 
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CHAPTER 2: Iron-sulfur cluster proteins and apicoplast maintenance  
ABSTRACT 
The apicoplast is an organelle that is essential for the survival of Pf, the deadliest species among the 
five which cause human malaria. Although the protozoan parasite falls under the domain Eukarya, its 
plastid houses several pathways of bacterial origin, including the SUF pathway of [Fe-S] cluster 
biosynthesis, which has been shown to be required for the maintenance of the organelle. While prior 
studies have helped elucidate the organellar localization of, as well interactions between, specific 
proteins that utilize and/or help assemble [Fe-S] clusters in Plasmodium spp., a systematic examination 
of the essentiality of each individual protein for ABS Pf survival and apicoplast maintenance is wanting. 
To help address this, we employed a genetically engineered Pf bypass line (PfMev), to which exogenous 
supplementation of Mevalonate, a precursor metabolite of mammalian isoprenoid biosynthesis, 
enables the survival of parasites that have lost the organelle. From this parental line, we generated 
genetic knock-outs of individual, or pairs of, apicoplast-localized proteins that are involved with the 
utilization and/or assembly of [Fe-S] clusters. Among the thirteen proteins examined, we show that 
the one(s) involved with sulfur mobilization (SufS and SufE), cluster assembly (SufC and SufD), 
cluster transfer (NifU and SufA together but not individually), isoprenoid biosynthesis (DXPR, IspG, 
and IspH), and redox (Fdx) are indispensable for ABS Pf survival, while those involved with tRNA 
thio/methylation (MiaB) and lipoic acid metabolism (LipA) are dispensable. Furthermore, among the 
proteins examined, only MnmA and SufS, both of which utilize sulfur to carry out their respective 










[Fe-S] clusters in Plasmodium spp.  
Iron-sulfur clusters are inorganic prosthetic groups attached to specific proteins. These clusters are 
thought to serve as cofactors required for the proper functioning of the associated proteins, and can 
come in various forms, among which the most common are binuclear [2Fe-2S], cuboidal [3Fe-4S], 
and cubane [4Fe-4S] clusters. Plasmodium spp. harbor two functional [Fe-S] cluster biosynthesis 
pathways – the mitochondrion-localized iron-sulfur cluster (ISC) pathway and the apicoplast-localized 
sulfur utilization factors (SUF) pathway. As shown in the putative model for [Fe-S] cluster biosynthesis 
within the apicoplast (Figure 2.1), this pathway is thought to involve a total of seven SUF proteins 
(SufS, E, B, C, D, A, and U), most of which have been localized to the apicoplast – SufC was localized 
to the apicoplast in Pf [1]; SufS, E, and D were localized to the apicoplast in Plasmodium berghei (Pb) [2]; 
SufS and E were exclusively localized to the apicoplast in ABS Pf [3]; and NifU (a.k.a. SufU) was 
localized to the apicoplast in Pb [4]. Among these seven proteins, only SufB is specifically encoded by 
the apicoplast genome. As SufS, E, C, D, A, and U are encoded by the nuclear genome, these six 
proteins must be targeted specifically to the apicoplast (for a more detailed discussion of apicoplast-
targeting of nuclear-encoded proteins, see the INTRODUCTION section of CHAPTER 4). 
[Fe-S] cluster biosynthesis within the apicoplast is thought to be initiated by SufS, which, 
together with its interacting partner SufE, mobilizes sulfur from L-cysteine. Furthermore, SufE is 
thought to form a complex with SufS and enhance the cysteine desulfurase activity of SufS [5]. 
Although L-cysteine has been identified as a source of sulfur for assembling [Fe-S] clusters, the source 
of iron is unidentified as of yet. Nonetheless, the mobilization of iron and sulfur is thought to be 
followed by cluster assembly on a scaffold protein complex that takes the form of SufB-C2-D [6]. 
Evidence for this comes from the in vitro demonstration of the complex formation between SufB and 





presence of the scaffold complex [6]. Lastly, the assembled [Fe-S] clusters are transferred via NifU 
and/or SufA to specific [Fe-S] cluster-utilizing proteins. Evidence for this comes from the in vitro 
demonstration of the preference of both cluster transfer proteins to bind [4Fe-4S] clusters and their 
capability of transferring the bound cluster onto E. coli aconitase B, a known [4Fe-4S] cluster-utilizing 
protein [6].  
 
Figure 2.1. A model for the SUF pathway in the apicoplast of Plasmodium spp. SufS and SufE 
together initiate sulfur mobilization from L-cysteine. SufS acquires a sulfur from L-cysteine, thereby 
forming a persulfide group. Thereafter, this sulfur from the persulfide group of SufS is passed along 
to SufE, which then transfers it to the SufB-C2-D scaffold complex, on which cluster assembly takes 
place. The iron used for assembling [Fe-S] clusters is derived from an unidentified source. Finally, 
NifU and/or SufA transfers the assembled clusters to specific [Fe-S] cluster-utilizing proteins. Note, 
for simplicity, only a [4Fe-4S] type cluster is depicted (for a comprehensive list of apicoplast-localized 
[Fe-S] cluster-utilizing proteins and their associated cluster type, see Figure 2.3 below).  
 
Now, although components of the SUF pathway have been identified, and steps to the cluster 
assembly process have been largely elucidated, the potential role of this pathway in the maintenance 
of the apicoplast has yet to be determined. From an experimental perspective, this is a particularly 





of Plasmodium spp., direct genetic deletion of any protein that is required for maintaining this organelle 
would automatically result in the death of the parasite; (2) as evidenced from in vitro [Fe-S] cluster 
reconstitution experiments, the clusters are oxygen-sensitive and rapidly degrade under aerobic 
conditions. To circumvent these issues, we have genetically engineered a Mevalonate bypass Pf line, 
PfMev, to which exogenous supplementation of Mevalonate, a precursor metabolite of mammalian 
isoprenoid biosynthesis, enables the survival of parasites that have lost the organelle.  
 
The design of the Mevalonate bypass line PfMev  
Isoprenoids are polymers of either IPP or its isomer DMAPP, and can serve at least three purposes 
in Pf: (1) prenyl transferases can catalyze the prenylation of specific proteins using polymers of IPP or 
DMAPP [8]; (2) isoprenoids can be incorporated into dolichols [9], which are a group of organic 
compounds involved in the formation of glycoproteins; and (3) isoprenoids are needed for the 
synthesis of quinones (ubiquinone and menaquinone), which are a part of the electron transfer system 
within the mitochondrion. Two functional pathways exist for the biosynthesis of isoprenoids: (1) the 
Mevalonate-dependent pathway, or MVA pathway (Figure 2.2A), utilized by mammalian cells, and 
(2) the Mevalonate-independent pathway, or MEP pathway (Figure 2.2B), located within the 
apicoplast. Although both pathways result in the synthesis of isoprenoid precursors IPP and DMAPP, 
the two routes differ with respect to their starting materials, intermediates, as well as enzymes. More 
specifically, the Mevalonate-dependent pathway starts with two molecules of acetyl CoA, which are 
converted to Mevalonate via a series of reactions catalyzed by three enzymes. This Mevalonate then 
gets converted to IPP/DMAPP by four enzymes – MVK, PMK, MPD, and IDI. The Mevalonate-
independent pathway, on the other hand, does not generate Mevalonate as an intermediate. Rather, 
the starting materials pyruvate and GA3P are converted to IPP and DMAPP through the action of 





Fosmidomycin, an antimalarial which targets the Mevalonate-independent pathway by 
inhibiting DXPR [10], induces growth arrest in Pf [10, 11]. However, supplementation with IPP alone 
rescues the parasites from this drug-induced phenotype [11], thereby indicating that, as long as IPP is 
available to ABS Pf, precursor molecules to IPP biosynthesis and enzymes lying upstream of IPP are 
dispensable for the survival of the parasite. Moreover, IPP supplementation enables the survival of 
ABS Pf parasites which have lost the apicoplast [11], indicating that it is not the apicoplast per se, but 
rather, the presence of specific isoprenoids generated within this organelle, that is required for the 
survival of ABS Pf. In that regard, IPP supplementation offers a metabolic bypass that enables the 
survival of parasites in which proteins that are needed for maintaining the apicoplast are somehow 
lost. Unfortunately, however, such a bypass system is rendered infeasible via the prohibitive cost of 
directly purchasing the molecule as well as the impracticality of its chemical synthesis. To overcome 
this hurdle, we have genetically engineered the PfMev line, which cytosolically expresses four enzymes 
of the Mevalonate-dependent pathway – MVK, PMK, MPD, and IDI. As outlined in the pathway 
(Figure 2.2A), these four enzymes convert Mevalonate to IPP/DMAPP. Therefore, as long as 
Mevalonate is provided in the growth medium for this bypass line, the parasites that have lost the 
apicoplast will be able to survive. Given this, the PfMev line allows us to delete any gene from the 
parasite, irrespective of whether the corresponding encoded protein is required for the survival of the 
parasite, and examine the aftermath of the deletion. With this bypass system in hand, therefore, we 
are able to address our initial question – how are [Fe-S] cluster proteins important to the maintenance 
of the apicoplast? To that end, we have generated thirteen PfMev-based genetic knock-out lines, each 
of which is either a single or double deletion mutant. The overall schematic illustrating the bypass 
system as well as pathways involving the proteins of interest to this study are shown below (Figure 
2.3). With the exception of MnmA and DXPR, each protein targeted by our knock-out approach has 






Figure 2.2. The two pathways of isoprenoid biosynthesis. (A) The Mevalonate-dependent 
pathway and (B) the Mevalonate-independent pathway of isoprenoid biosynthesis are shown. The 
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Figure 2.3. The PfMev bypass pathway. Mevalonate provided in the growth medium will enter the 
parasite cytosol, where it gets converted to IPP/DMAPP by four cytosolically expressed enzymes of 
the Mevalonate-dependent pathway. Given that isoprenoid biosynthesis is essential for the survival of 
ABS Pf, this supplementation enables the survival of parasites in which endogenous IPP biosynthesis 
is disrupted. Components of the bypass system are highlighted in blue; the thirteen Pf proteins targeted 
by our genetic knock-out strategy are highlighted in yellow. Among the five [Fe-S] cluster-utilizing 
proteins, IspG, IspH, LipA, and MiaB each has a [4Fe-4S] cluster, while Fdx has a [2Fe-2S] cluster. 
Among the thirteen targeted proteins, DXPR and MnmA are the only ones that are not known to be 








MATERIALS AND METHODS  
Parasite culture maintenance  
Each parasite culture was maintained at 1% hematocrit (using human blood) in 10 mL total volume 
in a 75 cm2 sealed cell culture flask (Corning, cat. #430168) at 37oC. Each flask contained Complete 
Medium with AlbuMAX (CMA): RPMI 1640 medium (USBiological Life Sciences, cat. #R8999) 
supplemented with 25 mM HEPES (Sigma-Aldrich, cat. #H4034), 0.375% Sodium Bicarbonate (gibco, 
cat. #25080-094), 12.5 µg/mL Hypoxanthine (Sigma-Aldrich, cat. #H9377), 5 g/L AlbuMAX II 
(gibco, cat. #11021-037), and 25 µg/mL Gentamicin (Sigma-Aldrich, cat. #G3632), with or without 
50 µM Mevalonate (Sigma-Aldrich, cat. #M4667). Prior to sealing the flask for incubation at 37oC, the 
flask was gassed with 94% N2, 3% O2, 3% CO2 for 40 seconds.  
The present study examined thirteen PfMev-based knock-out lines, among which only LipA 
and MiaB are not dependent on Mevalonate for survival based on our experiments. For these two 
lines specifically, therefore, the parasites were cultured in pure CMA medium for approximately 2 
weeks prior to taking samples for the subsequent growth curve experiments. This eliminates any 
parasites that have spontaneously lost the apicoplast from the culture.  
 
Genotyping PCR  
For each knock-out line, a corresponding set of four PCR reactions was performed to ascertain the 
genotype of the knock-out. The four reactions were designed to detect either the 5’ and 3’ regions of 
the WT gene (5’ and 3’) or the 5’ and 3’ regions consistent with gene deletion (Δ5’ and Δ3’) (Figure 
2.4). For each knock-out line, the same set of four PCR reactions performed on the knock-out line 
was performed on the parental PfMev line, which served as a WT control (Figure 2.4). Briefly, when 
the parasitemia for a culture was sufficiently high (about 5 – 8%) as determined via Giemsa staining, 





centrifuged at 6,500 rpm for 5 minutes. The supernatant was collected and stored at -20oC until the 
time of use. All PCR reactions were carried out with an ABI GeneAmp PCR system 9700 using the 
Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific, cat. #F530L), and the products 
were visualized on a 1.5% agarose gel. The reaction setup, thermal cycling conditions, and primer 




sample 1 µL temperature time 
5X HF buffer 10 µL 95°C 3'50''
F primer (10 µM) 1.5 µL 95°C 0'30'' 35 cycles 
R primer (10 µM) 1.5 µL 62°C 1'00''
dNTP (10 mM) 1 µL 62°C 4'00''
phusion 0.5 µL 64°C ∞
Milli-Q water 34.5 µL
total vol. 50 µL
Primer name Primer sequence 
pl8insHA1F GCTATTTAGGTGACACTATAGAATACTCAAGC 
pl8insHA2R AATCTAGAATTCGACAGACGCCGG 
MnmA 5’F CTACTTTGATGTTTTTTTATTTTTGCACATTTTATG 
MnmA 3’R GGTATTTTTTATTTGCTCATGTTTAAATCATTTATCTG 
MnmA 5’WT R CTTTATACTATTGTTTCTTTGTTCGTCTTCATCAATTTG 
MnmA 3’ WT F CTTACTAAAAATTATGACCAAGATTTATTTACACATATACG 
SufS 5’F CAGAAAATGAGTGAGTTTTATAAAAAGGAAAACTC 
SufS 3’R CAATTTGCTGTGCCAAATATTTGATTTC 
SufS 5’WT R CCATATAACAATGGTTTAAATTTATATTTTGATG 
SufS 3’ WT F CCAGATATATTAATAACATCTGGTCATAAATTTTG 
SufE 5’F CATTTCATTCATTTTGGTAGTTAAAAAGAAAAGG 
SufE 3’R TCATTTTATTAAAAACATATTTCATTTAATTTGTAAGA 
SufE 5’WT R CATGAGCATATTATATATAAAACAAAGAAATGTGC 
SufE 3’ WT F CCTGATAAACATAAAATTAGACAAAATCAAGTTTTGG 
SufC 5’F GGGATTTGTCATACATATAAATATGTATAAAAAGGTCC 
SufC 3’R TAAGTACAAAATAATATCATATGTACATTATAAAATCCAC 
SufC 5’WT R CTTCTTCTAAATTTTTTAATAAAGATAATCTATCCATATC 
SufC 3’ WT F GAGATAAGTGTAAGTGAATTTAATTTAATGATGATAGAAG 
SufD 5’F GTGTATATAATTTTTTGAAAAAAATGATTTAGCTAACACA 
SufD 3’R CAGATATTCCTCTTGTCATTAATGAGAAGATTGG 
SufD 5’WT R GTGTTTTCTCTTCATTTTGATGTCTATAGTTTTTTATAC 
SufD 3’ WT F CCAATAACAAATCCTAGATTAGTTGTATATGTAAAAGG 










NifU 3'R CGTTAATGTGGAGAAAATTCAAAGACCTAC 
NifU 5' WTR CGAAATTATTTTGTATAAATAACACCTTTGC 
NifU 3' WTF CACACAACGTTAAAAATGAAATAACAGAAAG 
SufA 5'F CTTTTTTCTCCTTTTAATATTAAAAAGAAAAAAG 
SufA 3'R CCTAAAGATATATATTTATGTGTTATCTTATATATTTTTG 
SufA 5' WTR GCTCTTATTGTTATATAAAAATGTTTTTGGAG 
SufA 3' WTF GATATAGAACGAAATTGAAGAAGATGATTATATAC 
DOXP 5' F CTATTAATGATTTAGTAATAAATAATACATCAAAATGTG 
DOXP 3'R GTATTTTATTTTTTTTTGTACTATGAAGAATTATGTTTG 
DOXP 5' WT R CCTTGAAAAGAATCAATACCAATAACTATTTTATC 
DOXP 3' WT F GGAAAATGGGTAAGAAAATAACTATAGATTCTG 
IspG 5' F CTAAATGAAGAAGGGAATTCTTCAAAAAAG 
IspG 3' R CATATTCAATTTATGGATCTTTCCATTTG 
IspG 5' WT R CAATACATAAATCAGAAAACTCAAAAGCC 
IspG 3' WT F GTATTAATAACCAGAAGAATTAATGAACTTTTACAATC 
IspH 5' F CCAGTAAGCAAAATATATCCATTCTGTATAC 
IspH 3' R TGTGATTTCATTTTTCTCTTTCTTTTATCA 
IspH 5' WT R GGGTACATATATATTTTTCGATTCCCATC 
IspH 3' WT F CCATTAAATAAAAAGTTATTCTATGTTACACAAACC 
Fdx 5'F CTGGTATATTATAGTTTATATTTAATAAGAAAAGGGC 
Fdx 3'R GGTAGCGAAGTTAATACATACACATATATATATGTG 
Fdx 5' WT R CGAATGTAATGAAGATGAATATATATTAGATGCTAG 
Fdx 3' WT F GGTAGCGAAGTTAATACATACACATATATATATGTG 
LipA 5' F CCTACATAAACTGTAATGTTTCAATATGACC 
LipA 3' R GGTTAACTAAATTTTTTATAAAATATTCACCTGC 
LipA 5' WT R GTGCTTCTTCACATACGGTATGTAAG 
LipA 3' WT F CTTTCAATACAGCTAAAGCTATATGTGAATG 
MiaB 5’F GATATTAAATGGGAAAGCAAAACTTATAAGTTTTTTATTC 
MiaB 3’R GTGATACATTTTCAAATATCTCCATATCTTTTTCTG 
MiaB 5’ WT R GATGTTGATAAGCATTCCAAGTCATATTCTC 






Figure 2.4. General genotyping PCR scheme. The SufA genomic locus is shown as an example. 
For each knock-out line, a set of four genotyping PCR reactions was performed. These reactions, 
designated as Δ5’, Δ3’, 5’, and 3’, along with the identity of forward and reverse primer per reaction, 
are indicated. For the WT genomic locus, amplicons are only expected for the reactions 5’ and 3’; for 
the disrupted locus, amplicons are only expected for the reactions Δ5’and Δ3’.  
 
Organellar genome PCR  
For each knock-out line, the status (presence or absence) of the nuclear and organellar genomes was 
determined by amplifying the LDH (nuclear genome), SufB (apicoplast genome), and Cox1 
(mitochondrial genome) genes. Samples were collected in the same fashion as mentioned above for 
genotyping PCR. For each knock-out line, the same set of three PCR reactions performed on the 
knock-out line was performed on the parental PfMev line, which served as a WT control. The reaction 
setup, thermal cycling conditions, and primer sequences are as follows: 
 
Δ3' Δ5'
WT SufA locus 
5’ 3’
Δ3' Δ5'
SufA locus with drug res. cassette incorporated  
5' 3'
primer combo F primer R primer
Δ5' PL8 HA2 F II SufA   3' R
Δ3' SufA   5' F II PL8 HA1 R 
Δ5' SufA   5' F II SufA   5' WTR
















Generation of growth curves  
Growth curves were generated using a plate-based SYBR Green assay. As illustrated in the overall 
plan (per IC plate) used to generate growth curves for the thirteen PfMev-based knock-out parasite 
lines (Table 2.1), each growth curve spans 4 days (from day 0 to day 4), and the parasitemia from each 
day was measured using flow cytometry. The following subsections detail each step of the overall plan. 
 
Table 2.1. The overall plan (per incubator [IC] plate) for growth curve generation. This overall 
plan was used to generate growth curves for the thirteen PfMev-based knock-out parasite lines. 
 
sample 1 µL temperature time 
5X HF buffer 10 µL 95°C 3'30''
F primer (10 µM) 1.5 µL 95°C 0'30'' 35 cycles 
R primer (10 µM) 1.5 µL 63°C 0'30''
dNTP (10 mM) 1 µL 72°C 0'45''
phusion 0.5 µL 72°C 4'00''
Milli-Q water 34.5 µL 64°C ∞
total vol. 50 µL
Primer name Primer sequence 
LDH F GGAGATGTAGATTTGTTCGATATTG 
LDH R CTTGTAAAGGGATACCACCTACAG 
SufB FII CATGTAGCTATAGTAGAAATAATAGTA 
SufB R GACTCTGAAATACTTAAACCACGTTGC 
Cox1 F CTTCATCTTTAAGAATAATTGCACAAGAAAATGTAAATC 





Flow cytometry  
Seeding  
The parasitemia of each parasite line was determined using Giemsa staining. Based on this parasitemia, 
quadruplicate samples were seeded in a 96-well flat-bottom cell culture plate (Corning, cat. #3595) at 
0.5% parasitemia (pt), 2% hematocrit (hc), and 250 µL total volume per well.  
For each parasite line, a master mix containing the appropriate amount of culture content, 50% 
hematocrit blood, and enough CMA media to bring the total volume to 10 mL was prepared and 
centrifuged at 1,600 rcf at room temperature (~25oC) for 5 minutes. After removal of the media via 
aspiration, the cell pellet was resuspended in CMA medium, and spun again under the same centrifuge 
settings. Post media removal after the second spin, the cell pellet was resuspended in the appropriate 
amount of CMA medium, and equally split into two tubes. To one of the two tubes, the appropriate 
amount of 10 mM Mevalonate stock solution (in sterile water) was added to yield a final concentration 
of 50 µM Mevalonate. Thereafter, each sample was seeded at 250 µL per well. In order to prevent any 
evaporation from the edge wells, a moat consisting of 1 mM EDTA was prepared around the sample 
wells at 250 µL per well. The prepared plate was placed into a Modular Incubator Chamber (Billups-
Rothenberg Inc., MIC-101), and gassed with 94% N2, 3% O2, 3% CO2 for 1 minute and 15 seconds 
prior to incubation at 37oC. Immediately post seeding, the parasitemia for each seeded well was 
measured by flow cytometry (see below for details) to confirm the accuracy of the seeded parasitemia. 
 
Sample collection and storage 
Samples were collected at the approximate 24, 48, and 72 hour time points (on days 1, 2, and 3, 
respectively) post seeding (Table 2.1). Each sample that was collected from days 1 – 3 was diluted 
1:10 by the type of media within the well from which the sample was derived, and stored in a 96-well 





observations, this storage protocol preserves the sample parasitemia for at least three overnights (see 
the RESULTS AND DISCUSSION section for details). 
 
SYBR Green staining 
SYBR Green staining was carried out in a 96-well round-bottom cell culture plate (Corning, cat. #3359) 
under protection from light. 100 µL of 1X SYBR Green (Invitrogen, cat. #S7563) in 1X phosphate-
buffered saline (PBS) (pre-warmed to 37oC) was deposited into each well, followed by 1 µL of a 2% 
(or 10 µL of 0.2%) hematocrit sample. Then, the plate was incubated for 30 minutes under protection 
from light on a vibrating platform shaker at 950 rpm. After incubation, 150 µL of 1X PBS (pre-warmed 
to 37oC) was added to each well in order to dilute the excess unbound SYBR Green. When empty 
wells were available on the plate, an uninfected control (2% hematocrit in CMA) was prepared on the 
day of staining and treated in parallel with the rest of the samples on the plate.  
 
Cytometer gates and settings  
The day 4 samples, along with day 1 – 3 samples, were analyzed with an Attune Nxt Flow Cytometer 
(Thermo Fisher Scientific) on day 4. Parameters under the settings panel were set as follows: 50 µL 
for the Acquisition Volume; 250 µL for the Total Sample Volume; 25 µL/minute for the running 
speed; and 10,000 events within the R2 gate as the sample acquisition stopping point. The flow 






Figure 2.5. Flow cytometer gates. The R1 gate within the Forward Scatter-Area (FSC-A) by Side 
Scatter-Area (SSC-A) analysis (left panel) was used to identify total RBCs from each sample; the R2 
gate within the FSC-A by Forward Scatter-Height (FSC-H) analysis (middle panel) was drawn to 
isolate single cells from the total cells; the R3 gate within the SYBR Green fluorescence by Count 
analysis (right panel) was drawn to give the parasitemia (the percent of SYBR Green-positive single 
RBCs out of all single RBCs).  
 
Limiting dilution  
Seeding  
Single cloning of each knock-out parasite line was carried out via limiting dilution. For each parasite 
line, the type of medium used for the initial dilution and subsequent media changes is the same as that 
within the flask from which the sample was derived. The parasitemia for each culture was determined 
using Giemsa staining, and used to calculate the number of infected RBCs (iRBCs) per µL of culture. 
Based on this iRBC concentration, a sample consisting of 1,000 iRBCs/µL was prepared. This sample 
was then diluted 1:10 thrice sequentially, yielding a parasite sample with a final concentration of 1 
iRBC/µL. Each well of a 96-well flat bottom cell culture plate (Corning, cat. #3595) was filled with 
200 µL of growth medium with 2% hematocrit RBCs. 100 µL of the 1 iRBC/µL parasite solution was 





to row, starting from row A and all the way down to row H. The prepared plate was placed into a 
Modular Incubator Chamber (Billups-Rothenberg Inc., MIC-101), and gassed with 94% N2, 3% O2, 
3% CO2 for 1 minute and 15 seconds prior to incubation at 37
oC. 
 
Media change and culture maintenance  
After seeding on day 0, the media was changed on days 5, 7, 9, 12, and 14. On days 5 and 12, a 0.5% 
hematocrit medium was used to replace lost RBCs; on days 7, 9, and 14, pure medium (without any 
blood) was used; on day 16, selected iRBC-positive wells that were the farthest down in the dilution 
series (i.e., closest to row H) were picked and transferred into a 24-well flat bottom cell culture plate 
(Corning, cat. #S3524) at 2% hematocrit and 1 mL total volume per well. The 24-well plate was then 
maintained and routinely monitored. Upon reaching a high enough parasitemia (~8%), the content 
within the well was transferred into a 75 cm2 sealed cell culture flask (Corning, cat. #430168) and 
further maintained under normal culture conditions. For each cloned parasite line, the genotype and 















RESULTS AND DISCUSSION  
Confirmation of the knock-out genotype 
After generating the thirteen PfMev-based knock-out lines, we first confirmed the genotype of each 
knock-out. As shown in the general genotyping scheme (Figure 2.4), amplicons are expected for the 
reactions Δ5’ and Δ3’ only for each knock-out line, while amplicons are expected for the reactions 5’ 
and 3’ only for the WT control. In this fashion, our genotyping PCR results confirmed the genotype 
of each knock-out and indicated an absence of any contamination by WT parasites for each knock-
out line (Figure 2.6A’ – M’).  
 
Optimization of the flow assay  
Having ascertained the genotype of each knock-out line, we proceeded to validate the essentiality of 
each protein examined herein with respect to the survival of ABS Pf. To that end, we sought to 
compare the growth of each knock-out line in the presence of Mevalonate vs. its growth without such 
supplementation, over a span of 4 days (from day 0 to day 4). For all growth curves generated herein, 
the parasitemia for the seeded samples were measured on day 0 in order to confirm the accuracy of 
the seeding. As for the days 1 – 3 samples, we wanted to avoid measuring the parasitemia on a daily 
basis, and thus tested whether sample storage under 4oC (without using a fixative) is able to preserve 
the parasitemia. As shown in our results (Table 2.2), storage of samples under 4oC is able to preserve 
the parasitemia for at least three days. Thus, for all the growth curves, the days 1 – 3 samples were 









Table 2.2. Validation of the cold room storage method. A comparison of the parasitemia derived 
from the same sample with or without storage at 4oC is shown. CR (cold room) denotes samples that 
were stored at 4oC and analyzed on day 4; IC (incubator) denotes samples that were analyzed on the 
day of sample collection, without undergoing any prior storage at 4oC. Results are shown for three 




Figure 2.6. Organellar genome/genotyping PCR for thirteen PfMev-based knock-out lines. 
Results for organellar genome PCR amplifying the LDH, SufB, and Cox1 gene from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genome, respectively, are shown for the knock-out lines (A) 
ΔMnmA, (B) ΔSufS, (C) ΔSufE, (D) SufC, (E) SufD, (F) ΔSufC ΔSufD, (G) ΔNifU ΔSufA, (H) 
ΔDXPR, (I) ΔIspG, (J) ΔIspH, (K) ΔFdx, (L) ΔLipA, and (M) ΔMiaB. Results for genotyping PCR 
are shown for the knock-out lines (A’) ΔMnmA, (B’) ΔSufS, (C’) ΔSufE, (D’) SufC, (E’) SufD, (F’) 
ΔSufC ΔSufD (for the SufC genomic locus), (F’’) ΔSufC ΔSufD (for the SufD genomic locus), (G’) 
ΔNifU ΔSufA (for the NifU genomic locus), (G’’) ΔNifU ΔSufA (for the SufA genomic locus), (H’) 
ΔDXPR, (I’) ΔIspG, (J’) ΔIspH, (K’) ΔFdx, (L’) ΔLipA, and (M’) ΔMiaB. The genotyping PCR 
reactions designated Δ5’, Δ3’, 5’, and 3’ correspond to those shown in Figure 2.4. For each PCR 
reaction for both types of PCR, the PfMev line was included as a WT control. The results shown for 
ΔMnmA and ΔSufS are from polyclonal parasites, while the results shown for the remaining knock-
out lines are from monoclonal parasites.  
0.3% starting parasitemia 0.5% starting parasitemia   1% starting parasitemia 
day IC CR IC CR IC CR
1 0.69% 0.71% 1.36% 1.39% 2.10% 1.65%
2 1.24% 1.72% 1.52% 1.22% 3.76% 4.55%
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Figure 2.7. Growth curves for PfMev and four PfMev-based knock-out lines. Parasites were 
seeded at 0.5% parasitemia on day 0 and allowed to grow up to day 4. As indicated, two different 
media conditions were used for each line: CMA with or without 50 µM Mevalonate. Each data point 
(error bar) represents the mean (standard deviation) derived from four technical replicates. For any 
data point, the apparent absence of an error bar is due to its small size. (A) The PfMev line 
(synchronized) served as a control demonstrating Mevalonate-independence. (B) ΔLipA and (C) 
ΔMiaB show Mevalonate-independence. (D) ΔMnmA and (E) ΔSufS show Mevalonate-dependence. 
Growth curves for proteins that are required for the maintenance of the apicoplast in ABS Pf are 
shown in the blue panels; growth curves for proteins that are dispensable for ABS Pf are shown in the 
grey panels (see text under the RESULTS AND DISCUSSION section for details).  




































































































































Figure 2.8. Growth curves for nine PfMev-based knock-out lines. Non-synchronous parasites 
were seeded at 0.5% parasitemia on day 0 and allowed to grow up to day 4. As indicated, two different 
media conditions were used for each line: CMA with or without 50 µM Mevalonate. Each data point 
(error bar) represents the mean (standard deviation) derived from four technical replicates. For any 
data point, the apparent absence of an error bar is due to its small size. Each of the nine lines shown 
exhibits Mevalonate-independence: (A) ΔFdx, (B) ΔSufE, (C) ΔNifU ΔSufA, (D) SufC, (E) SufD, 
(F) ΔSufC ΔSufD, (G) ΔDXPR, (H) ΔIspG, and (I) ΔIspH. All of the lines shown are essential for 
the survival of ABS Pf, but are not required for the maintenance of the apicoplast (see text under the 
RESULTS AND DISCUSSION section for details). 



















































































































































































































A recent study done on Pb attempted to delete all SUF genes except for SufB (SufS, E, C, D, and A) 
but was only successful in generating viable SufA mutants, suggesting that SufS, E, C, and D are 
required for the propagation of blood stage infection, while SufA is dispensable for that purpose [2]. 
Herein, we have examined thirteen PfMev-based knock-out lines using flow cytometry and organellar 
genome PCR. Among the proteins that were knocked out, MnmA, SufS, SufE, SufC, SufD, NifU and 
SufA (together but not individually), DXPR, IspG, IspH, and Fdx were shown to be indispensable 
for the survival of ABS Pf, while LipA and MiB were shown to be dispensable for the survival of ABS 
Pf. Furthermore, among these proteins, only SufS and MnmA were shown to be required for the 
maintenance of the apicoplast in addition to parasite survival (Table 2.3). Taken together at face value, 
these data suggest the three following conclusions: 
(1) MnmA and SufS are required for the survival of ABS Pf in that these proteins are required for 
the maintenance of the apicoplast.  
(2) SufC, SufD, NifU and SufA (together but not individually), DXPR, IspG, IspH, and Fdx are 
required for the survival of ABS Pf due to reasons other than being required for maintaining 
the apicoplast.  












Table 2.3. Summary of organellar genome PCR and flow cytometry results. Results are shown 
for PfMev and thirteen PfMev-based knock-out lines. Indicated for each parasite line are Mevalonate-
(in)dependence and organellar genome status (presence vs. absence). The various proteins examined 
can be classified into three categories according to the same color-coding for the panels of Figure 2.7 
and Figure 2.8: those that are essential by being required for apicoplast maintenance (blue), essential 
due to reasons other than being required for apicoplast maintenance (yellow), and non-essential (grey). 
 
 
SufS and SufE 
In Pb, SufS has been shown to be important for the development of sporozoites present within the 
oocysts in the mosquito vector, suggesting that the protein is essential for Plasmodium development 
during the mosquito stage, and possibly other developmental stages of the parasite as well [6]. 
Consistent with this, our results show that SufS is needed for the survival of ABS Pf (Figure 2.7E), 
and that this essentiality can be attributed, at least in part, to the requirement of the protein for the 
maintenance of the apicoplast (Figure 2.6B). In addition, we have shown herein that SufE, the 
Line Mev-dependent Nuclear genome Apicoplast genome Mito. genome
(1) ΔMnmA + + - +
(2) ΔSufS + + - +
(3) ΔSufE + + + +
(4) ΔSufC + + + +
(5) ΔSufD + + + +
(6) ΔSufC ΔSufD + + + +
(7) ΔNifU ΔSufA + + + +
(8) ΔDXPR + + + +
(9) ΔIspG + + + +
(10) ΔIspH + + + +
(11) ΔFdx + + + +
(12) ΔLipA - + + +
(13) ΔMiaB - + + +





interacting partner of SufS, is required for the survival of ABS Pf (Figure 2.8B) but is not required 
for maintaining the apicoplast (Figure 2.6C). From a mechanistic perspective, SufS functions as a 
cysteine desulfurase that mobilizes sulfur from L-cysteine and subsequently transfers the liberated 
persulfide sulfur to SufE (Figure 2.1). Although Pf SufE by itself possesses no cysteine desulfurase 
activity, its ability to enhance the cysteine desulfurase activity of both E. coli and Pf SufS has been 
demonstrated in vitro [5]. In addition, the capability to complement the loss of E. coli SufS by Pf SufS 
has been shown [3]. Consistent with both proteins having a role in [Fe-S] cluster biosynthesis, we find 
that both SufS and SufE are essential for the survival of ABS Pf. In particular, the essentiality of SufE 
indicates that this protein is necessary for transferring sulfur to the SufB-C2-D scaffold complex and 
that SufS alone is not able to deliver sulfur to this complex. Taken together, these results suggest that 
SufS has an additional role in supporting apicoplast maintenance that is not shared by SufE (see below).  
 
MnmA 
Having demonstrated that SufS is required for the maintenance of the apicoplast, we sought to 
generate genetic knock-outs of sulfur-utilizing proteins from our PfMev line in order to understand 
why SufS is required for apicoplast maintenance. To that end, we chose to knock out MnmA, a thio-
uridylase involved in the post transcriptional modification of tRNAGlu, tRNAGln, and tRNALys [12], the 
tRNAs for the amino acids glutamate (Glu), glutamine (Gln), and lysine (Lys), respectively. Each of 
these three amino acids is encoded by two degenerate codons, each of which has a purine in the third, 
or wobble, position, thereby enabling the non-canonical base pairing between the first base of the 
tRNA anti-codon and the third base of the cognate mRNA codon. For these three tRNAs, the 2-thio-
uridine (s2U) modification of the wobble position is conserved in all three domains of life. The cysteine 
desulfurase IscS and MnmA from E. coli have been shown to be essential for s2U synthesis in vitro [12, 





is functionally analogous to E. coli SufS, and the co-expression of B. subtilis YrvO and B. subtilis MnmA 
in an E. coli IscS deletion strain was able to restore s2U synthesis [14]. From a mechanistic perspective, 
E. coli IscS serves as a cysteine desulfurase which catalyzes the reductive elimination of sulfur from L-
cysteine. This liberated sulfur is then relayed among five proteins and ultimately ends up with MnmA, 
which utilizes it in the s2U thiolation reaction [15]. Herein, we have shown that MnmA is required for 
the survival of ABS Pf (Figure 2.7D) and that it is also required for maintaining the apicoplast (Figure 
2.6A). This is the same phenotype that we observed for SufS (Figures 2.7E and 2.6B), suggesting 
that SufS might function in conjunction with MnmA in tRNA thiolation reactions that are essential 
for maintaining the apicoplast. More specifically, in E. coli, the absence of MnmA has been linked to 
an increase in the frequency of frameshift mutations during the translation process [16]. In addition, 
mutation of the gene encoding MnmA for both E. coli and Salmonella enterica was phenotypically linked 
to a reduction in growth in these bacteria, and such a defect was attributed to an inability of the 
mutants to synthesize mnm5s2U [17], an s2U derivative. Unfortunately, information on MnmA in 
Plasmodium spp. is nonexistent. However, if Pf MnmA fulfills a role analogous to that of its bacteria 
homologue, it is possible that, in ABS Pf, MnmA is required for ensuring the accuracy of translation 
for the nuclear and/or apicoplast genome. In that regard, ascertaining the organellar localization of 
MnmA via fluorescence microscopy should help narrow down whether the protein is required for 
successful translation within the apicoplast, the nucleus, or both.   
 
SufB, SufC, and SufD  
During [Fe-S] cluster assembly in the apicoplast of Pf, SufB, SufC, and SufD together form a so-called 
scaffold complex, on which cluster assembly then takes place. In Pf, the complex formation between 
SufB and SufD [6], SufC and SufD [6], as well as SufB and SufC [1, 6] have been demonstrated in vitro, 





Herein, our data indicate that SufC and SufD are both indispensable for ABS Pf survival (Figure 2.8D, 
E, and F), but are not required for apicoplast maintenance (Figure 2.6D, E, and F). Taken together, 
these data suggest that the [Fe-S] cluster scaffold complex is somehow required for the survival of 
ABS Pf, which is expected for two reasons based on the results presented herein. First, given that 
certain [Fe-S] cluster-dependent proteins (i.e., Fdx, IspG, and IspH) are required for ABS Pf survival 
(Figure 2.8A, H, and I), it is likely that the successful assembly of the complex is necessary to ensure 
that the [Fe-S] cluster-dependent proteins would successfully acquire the clusters, and thus be able to 
carry out their essential functions. Second, NifU and/or SufA serve to transfer the assembled [Fe-S] 
cluster to the aforementioned essential [Fe-S] cluster-dependent proteins. Given this, that the absence 
of cluster transfer led to the death of the parasites (Figure 2.8C) indicates that cluster assembly, 
transfer, and utilization are required for ABS Pf survival.  
As noted above, the ΔSufC parasites are dependent on Mevalonate for survival (Figure 2.8D), 
consistent with the IPP-dependence of the SufC dominant negative parasites shown in our earlier 
study [3]. In contrast with that previous study, however, the ΔSufC line presented herein has an intact 
apicoplast (Figure 2.6D). Such a discrepancy could be attributed, at least in part, to certain differences 
between the methods by which the two lines were generated. Specifically, generation of the 
SufC(K104A) dominant negative mutant involved the over-expression of an inactive mutant of the 
protein in which an active site lysine was substituted with an alanine [3]. Since the endogenous genomic 
locus remained unperturbed, endogenous SufC was presumably still expressed at a normal level. By 
contrast, generation of the ΔSufC line involved a disruption of the endogenous genomic locus (Figure 
2.4), thus yielding a complete cessation of SufC protein production from the parasite. Now, although 
the over-expression of SufC(K104A) with the strong calmodulin [PF14_0323] promoter could have 
generated additional stress that led to the loss of the apicoplast in the dominant negative study [3], a 





loss [3]. An alternative explanation is that the 200 µM IPP used as a chemical bypass in the dominant 
negative study, combined with the protein over-expression, created additional stress that was not 
mimicked by the Mevalonate bypass system used for the knock-out lines presented herein.  
In E. coli, the ATPase activity of SufC and the presence of SufD have both been demonstrated 
to be important for the acquisition of iron during [Fe-S] cluster assembly [18], and the same could 
hold true for the Pf orthologs of these proteins. Herein, we have shown that SufC is required for the 
survival of ABS Pf (Figures 2.8D and 2.6D), an observation that could be explained if the ATPase 
activity of Pf SufC, like that of its E. coli ortholog, is required for successful cluster assembly. In 
addition, the enhancement of the basal ATPase activity of SufC by SufD has been demonstrated in Pf 
in vitro [6]. Given that both SufC and SufD are individually required for ABS Pf survival (Figure 2.8D, 
E, and F), it is possible that this enhancement of the ATPase activity of SufC by SufD is required in 
order for SufC to attain sufficient activity to ensure successful scaffold assembly.  
 
NifU and SufA  
With respect to the propagation of blood stage infection, both NifU [4] and SufA [2] have been proven 
to be individually dispensable. Consistent with these results, we found that the deletion of either 
individual cluster transfer proteins confers no growth defect (data not shown), whereas the deletion 
of both proteins together results in the death of the parasite (Figure 2.8C). Analysis using UV/visible 
spectroscopy has shown that both NifU and SufA bind to [4Fe-4S] clusters, and the ability of both 
proteins to transfer the cluster has been demonstrated in vitro [6]. Presumably, the [2Fe-2S] cluster 
found on Pf ferredoxin (Fdx) [PMID: 17251200] is also transferred by these proteins. Herein, our gene 
deletion data show that NifU and SufA carry out redundant functions in cluster transfer, indicating 





phenotype of the NifU/SufA double deletion suggests that no other protein can fulfill the role of 
transferring [Fe-S] clusters in the apicoplast of malaria parasites. 
 
Fdx 
The apicoplast of Pf harbors a redox system comprised of Fdx and its redox partner ferredoxin 
NADP+ reductase (FNR). In photosynthetic plastids (i.e., chloroplasts of plants), FNR catalyzes the 
following light-dependent reaction: 2Fdxreduced (i.e., Fe
2+) + NADP+ + H+ → 2Fdxoxidized (i.e., Fe3+) + 
NADPH. Specifically, electrons from photosystem I are first transferred to Fdxoxidized to generate 
Fdxreduced. Thereafter, FNR catalyzes the transfer of these electrons from Fdxreduced to NADP
+, thereby 
generating Fdxoxidized and NADPH, which is either fed into the Calvin cycle to generate ATP or 
employed as a cofactor in anabolic reactions. In non-photosynthetic plastids such as the apicoplast 
and those of plant roots, however, the reaction is thought to proceed in the reverse direction to 
generate Fdxreduced, which can then act as a reductant for various metabolic reactions. Notably, a search 
of various Plasmodium genome databases identified the Pf homologue of plant Fdx proteins, along with 
an N-terminal bipartite pre-sequence characteristic of apicoplast-localized proteins [19] (for a more 
detailed discussion of apicoplast-targeting of nuclear-encoded proteins, see the INTRODUCTION 
section of CHAPTER 4). Furthermore, amino acid sequence alignment of the putative Pf Fdx with 
that of a subset of plant Fdx proteins revealed the presence, on the Pf Fdx, of the four well-conserved 
cysteine residues required for [2Fe-2S] cluster formation [19]. NMR chemical shift analysis identified 
three regions surrounding the [2Fe-2S] binding site within Pf Fdx that are responsible for the 
interaction of the protein with FNR, and specific acidic amino acid residues within these regions were 
confirmed, via site-directed mutagenesis, to be important for the physical as well as electron transfer 
interactions between Fdx and FNR [20]. Herein, we have shown that both Fdx (Figure 2.8A) and 





maintenance of the apicoplast (Figure 2.6K; data not shown). Taken together, these results indicate 
that the apicoplast redox system is required for the survival of ABS Pf, and that both Fdx and FNR 
are requisite components for a functional redox system.  
 
DXPR  
As the second step of isoprenoid precursor biosynthesis in the Plasmodium apicoplast, DXPR catalyzes 
the conversion of DOXP to MEP (Figure 2.2B). In the apicomplexan parasite Tg, the transit peptide 
of PfDXPR is capable of trafficking GFP to the apicoplast, thus indicating the apicoplast localization, 
in Pf, for DXPR as well as other components of the isoprenoid precursor biosynthesis pathway [10]. 
Importantly, the antibacterial fosmidomycin has been shown to inhibit the growth of ABS Pf in vitro 
by targeting DXPR [10], in accordance with the essentiality of isoprenoid biosynthesis for the survival 
of Pf [11]. Consistent with this, our data show that DXPR is required for the survival of ABS Pf, as 
evidenced by the Mevalonate-dependence of the ΔDXPR line (Figure 2.8G). Given the essentiality 
of the isoprenoid precursor IPP for the survival of Plasmodium [11], it is expected that any protein 
required for IPP biosynthesis (e.g., DXPR, IspG, and IspH) would be likewise indispensable, in line 
with our observations (Figure 2.8G, H, and I). However, although the DXPR is required for the 
generation of IPP, it is not required for the maintenance of the apicoplast (Figure 2.6H).  
 
IspG and IspH  
IspG and IspH catalyze the penultimate and ultimate reactions, respectively, of IPP biosynthesis 
(Figure 2.2B). UV/visible spectroscopy has demonstrated in vitro the presence of [4Fe-4S] clusters as 
prosthetic groups on E. coli GcpE [21] and LytB [22], the orthologs of Pf IspG and IspH, respectively. 
In Plasmodium, IspH catalyzes the simultaneous generation of IPP and DMAPP from HMBPP (Figure 





4S] cluster of IspH. In line with this, the Fdx/FNR pair of Pf has been shown to be capable of 
transferring electrons from NADPH to IspH in vitro [23], resulting in the generation of the expected 
isoprenoid precursors IPP and DMAPP [23]. Now, although analogous experiments were not 
performed with IspG, this indicates that the apicoplast Fdx/FNR redox system could function as an 
electron donor to IspH, and possibly other enzymes of the isoprenoid precursor pathway or even 
other metabolic pathways within the apicoplast. Therefore, although Fdx is not required for the 
maintenance of the apicoplast (Figure 2.6K), its requirement for the survival of ABS Pf (Figure 2.8A) 
is consistent with the notion that the Fdx/FNR redox system serves as a requisite electron donor to 
power the reaction catalyzed by IspH and possibly IspG as well as other important metabolic reactions 
within the organelle.  
 
LipA 
LipA is a [4Fe-4S] cluster-containing protein [3] that has been localized to the apicoplast [24]. LipA 
catalyzes the second step of lipoic acid synthesis by introducing two sulfur atoms, presumably derived 
from one of its two [4Fe-4S] clusters, into an octanoyl group that is bound to pyruvate dehydrogenase 
(PDH), an enzyme complex comprised of four subunits – E1α, E1β, E2, and E3. In Plasmodium yoelii, 
although deletion of the genes encoding either the E1α or E3 subunit ablated the capability of the 
ALS parasites to transition into the ABS, ABS development itself was not affected [25]. Furthermore, 
the E2 subunit of the PDH complex is responsible for generating acetyl CoA, a precursor for the 
FAS-II pathway. That being said, no growth defect in the ABS was evident upon the deletion of two 
of the enzymes in the FAS-II pathway, FabI [26, 27] and FabB/F [26]. As such, the dispensability of 
both the PDH complex as well as the FAS-II pathway for ABS Plasmodium development suggests that 
LipA should be likewise nonessential for ABS Pf, which is in accordance with our observations 






While data on MiaB in Plasmodium spp. is wanting, certain information on the Pf protein can be gleaned 
from studies on its E. coli ortholog. In E. coli, MiaA is thought to transfer the isopentenyl group derived 
from DMAPP to modify select tRNAs. More specifically, the isopentenyl group is attached to the N6 
(Nitrogen at position 6) of an adenosine base located at a particular position within the anti-codon 
region of the tRNA. The resulting isopentenylated tRNAs are then further modified by MiaB, a 
methyl-thiolase. UV/visible spectroscopy has demonstrated that, under reducing as well as anaerobic 
conditions, E. coli MiaB contains [4Fe-4S] clusters, which were observed to degrade to either [3Fe-4S] 
or [2Fe-2S] clusters upon exposure to air [28]. In addition, the [Fe-S] cluster of E. coli MiaB was shown 
to be required for the ability of the protein to modify tRNAs, as evidenced by site-directed mutagenesis 
experiments whereby specific conserved cysteine residues required for iron chelation were substituted 
with alanine [28]. Now, if MiaB is required for the maintenance of the apicoplast, the disruption of 
any of the components lying upstream of the protein should result in the loss of the organelle. That 
being said, since treatment of ABS Pf with fosmidomycin, an antimalarial that disrupts isoprenoid 
biosynthesis [10], does not lead to the loss of the apicoplast [3], it is expected that MiaB is not required 
for the maintenance of the apicoplast, just as we observed (Figure 2.6M). In addition, we have shown 
herein that MiaB is not required for the survival of ABS Pf (Figure 2.7C), suggesting that either (1) 
the tRNA modification function performed by this enzyme is non-essential to the parasite, or (2) the 
















[1] B. Kumar et al., “Interaction between sulphur mobilisation proteins SufB and SufC: evidence 
for an iron-sulphur cluster biogenesis pathway in the apicoplast of Plasmodium falciparum,” 
Int. J. Parasitol., vol. 41, no. 9, pp. 991–9, Aug. 2011. 
 
[2] J. M. Haussig, K. Matuschewski, and T. W. A. Kooij, “Identification of vital and dispensable 
sulfur utilization factors in the Plasmodium apicoplast,” PLoS One, vol. 9, no. 2, p. e89718, Feb. 
2014. 
 
[3] J. E. Gisselberg, T. A. Dellibovi-Ragheb, K. A. Matthews, G. Bosch, and S. T. Prigge, “The Suf 
Iron-Sulfur Cluster Synthesis Pathway Is Required for Apicoplast Maintenance in Malaria 
Parasites,” PLoS Pathog., vol. 9, no. 9, p. e1003655, Sep. 2013. 
 
[4] J. M. Haussig, K. Matuschewski, and T. W. A. Kooij, “Experimental Genetics of Plasmodium 
berghei NFU in the Apicoplast Iron-Sulfur Cluster Biogenesis Pathway,” PLoS One, vol. 8, no. 
6, p. e67269, Jun. 2013. 
 
[5] M. Charan, N. Singh, B. Kumar, K. Srivastava, M. I. Siddiqi, and S. Habib, “Sulfur mobilization 
for Fe-S cluster assembly by the essential SUF pathway in the Plasmodium falciparum 
apicoplast and its inhibition,” Antimicrob. Agents Chemother., vol. 58, no. 6, pp. 3389–98, Jun. 
2014. 
 
[6] M. Charan et al., “[Fe-S] cluster assembly in the apicoplast and its indispensability in mosquito 
stages of the malaria parasite,” FEBS J., vol. 284, no. 16, pp. 2629–2648, Aug. 2017. 
 
[7] D. Chakrabarti et al., “Protein prenyl transferase activities of Plasmodium falciparum,” Mol. 
Biochem. Parasitol., vol. 94, no. 94, pp. 175–184, 1998. 
 
[8] A. S. Couto, E. A. Kimura, V. J. Peres, M. L. Uhrig, and A. M. Katzin, “Active isoprenoid 
pathway in the intra-erythrocytic stages of Plasmodium falciparum : presence of dolichols of 
11 and 12 isoprene units,” Biochem. J., vol. 341, pp. 629–637, 1999. 
 
[9] H. Jomaa et al., “Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as 
antimalarial drugs,” Science, vol. 285, no. 5433, pp. 1573–6, Sep. 1999. 
 
[10] E. Yeh and J. L. DeRisi, “Chemical Rescue of Malaria Parasites Lacking an Apicoplast Defines 
Organelle Function in Blood-Stage Plasmodium falciparum,” PLoS Biol., vol. 9, no. 8, p. 
e1001138, Aug. 2011. 
 
[11] R. Kambampati and C. T. Lauhon, “Mnma and IscS are required for in vitro 2-thiouridine 
biosynthesis in Escherichia coli,” Biochemistry, vol. 42, no. 4, pp. 1109–1117, 2003. 
 
[12] Y. Ikeuchi, N. Shigi, J.-I. Kato, A. Nishimura, and T. Suzuki, “Mechanistic Insights into Sulfur 
Relay by Multiple Sulfur Mediators Involved in Thiouridine Biosynthesis at tRNA Wobble 






[13] K. A. Black and P. C. Dos Santos, “Abbreviated Pathway for Biosynthesis of 2-Thiouridine in 
Bacillus subtilis,” J. Bacteriol., vol. 197, no. 11, pp. 1952–62, Jun. 2015. 
 
[14] T. Numata, Y. Ikeuchi, S. Fukai, T. Suzuki, and O. Nureki, “Snapshots of tRNA sulphuration 
via an adenylated intermediate,” Nature, vol. 442, no. 7101, pp. 419–424, Jul. 2006. 
 
[15] J. Urbonavicius, Q. Qian, J. M. Durand, T. G. Hagervall, and G. R. Björk, “Improvement of 
reading frame maintenance is a common function for several tRNA modifications,” EMBO J., 
vol. 20, no. 17, pp. 4863–73, Sep. 2001. 
 
[16] K. Nilsson, H. K. Lundgren, T. G. Hagervall, and G. R. Björk, “The cysteine desulfurase IscS 
is required for synthesis of all five thiolated nucleosides present in tRNA from Salmonella 
enterica serovar typhimurium,” J. Bacteriol., vol. 184, no. 24, pp. 6830–5, Dec. 2002. 
 
[17] A. Saini, D. T. Mapolelo, H. K. Chahal, M. K. Johnson, and F. W. Outten, “SufD and SufC 
ATPase Activity Are Required for Iron Acquisition during in Vivo Fe-S Cluster Formation on 
SufB,” Biochemistry, vol. 49, pp. 9402–9412, 2010. 
 
[18] M. Vollmer, N. Thomsen, S. Wiek, and F. Seeber, “Apicomplexan parasites possess distinct 
nuclear-encoded, but apicoplast-localized, plant-type ferredoxin-NADP+ reductase and 
ferredoxin,” J. Biol. Chem., vol. 276, no. 8, pp. 5483–90, Feb. 2001. 
 
[19] Y. Kimata-Ariga, T. Saitoh, T. Ikegami, T. Horii, and T. Hase, “Molecular interaction of 
ferredoxin and ferredoxin-NADP+ reductase from human malaria parasite,” J. Biochem., vol. 
142, no. 6, pp. 715–720, Sep. 2007. 
 
[20] M. Seemann et al., “Isoprenoid Biosynthesis through the Methylerythritol Phosphate Pathway: 
The (E)-4-Hydroxy-3-methylbut-2-enyl Diphosphate Synthase (GcpE) is a [4Fe–4S] Protein,” 
Angew. Chemie Int. Ed., vol. 41, no. 22, pp. 4337–4339, Nov. 2002. 
 
[21] M. Wolff et al., “Isoprenoid biosynthesis via the methylerythritol phosphate pathway: The (E)-
4-hydroxy-3-methylbut-2-enyl diphosphate reductase (LytB/IspH) from Escherichia coli is a 
[4Fe-4S] protein,” FEBS Lett., vol. 541, no. 1–3, pp. 115–120, 2003. 
 
[22] R. C. Röhrich et al., “Reconstitution of an apicoplast-localised electron transfer pathway 
involved in the isoprenoid biosynthesis of Plasmodium falciparum,” FEBS Lett., vol. 579, no. 
28, pp. 6433–6438, 2005. 
 
[23] C. Wrenger and S. Müller, “The human malaria parasite Plasmodium falciparum has distinct 
organelle-specific lipoylation pathways,” Mol. Microbiol., vol. 53, no. 1, pp. 103–113, May 2004. 
 
[24] Y. Pei et al., “Plasmodium pyruvate dehydrogenase activity is only essential for the parasite’s 
progression from liver infection to blood infection,” Mol. Microbiol., vol. 75, no. 4, pp. 957–971, 
Feb. 2010. 
 
[25] A. M. Vaughan et al., “Type II fatty acid synthesis is essential only for malaria parasite late liver 






[26] M. Yu et al., “The Fatty Acid Biosynthesis Enzyme FabI Plays a Key Role in the Development 
of Liver-Stage Malarial Parasites,” Cell Host Microbe, vol. 4, no. 6, pp. 567–578, 2008. 
 
[27] F. Pierrel, G. R. Björk, M. Fontecave, and M. Atta, “Enzymatic modification of tRNAs: MiaB 






CHAPTER 3: Triclosan analogs as antimalarial drugs 
ABSTRACT  
Given the rapid rise of drug resistance in Pf parasites, there is a constant need for the discovery and 
development of novel effective antimalarials. Importantly, in order for a compound to be effective, it 
must not only exhibit potent antiparasitic activity but also possess parasitic molecular targets that are 
distinct from those of the previously employed drugs. That being said, one promising compound is 
triclosan. While an early study by Surolia and Surolia (2001) suggested that triclosan exerts its 
antimalarial effect by targeting Pf FabI, the FAS-II pathway has been later proven to be dispensable 
for the parasite during the ABS. Furthermore, a recent study has identified one of the Plasmodium 
targets of triclosan to be DHFR, which is one of the targets of the antimalarials sulfadoxine-
pyrimethamine (SP) and atovaquone-proguanil (AP), both of which were quickly met with resistance 
since their introduction. However, because studies have demonstrated the improved potency, over 
triclosan, of select analogs against the Dd2 Pf strain, which is resistant to both SP and AP, triclosan 
likely possesses other molecular targets that are distinct from those of SP and AP. With the hope of 
discovering the real molecular targets of triclosan-based antimalarials, we have screened seven 
triclosan analogs for their antiparasitic activity in ABS Pf. Through this screen, we have identified a 
compound, designated herein as djm-11-03A, to have outstanding antimalarial activity, with an IC50 
of 33 – 44 nM. Our next step is to induce drug resistance using this compound, which would help 











Triclosan (Figure 3.1A), a compound found in common household items such as toothpaste, soap, 
and plastics, exhibits activity against a broad spectrum of bacteria. An early study by Surolia and Surolia 
(2001) on the antimalarial activity of triclosan reported that the compound was able to inhibit 
Plasmodium growth both in vivo and in vitro, and that such activity can be attributed, at least in part, to 
the inhibition of enoyl-acyl carrier protein reductase (FabI) of the Plasmodium FAS-II pathway [1]. 
Given that the FAS-II pathway is entirely absent from human cells and given that the FAS-II pathway 
in Plasmodium spp. is localized to the apicoplast (an organelle that is essential to the parasite but absent 
from human cells), these initial results implicated triclosan as a promising antimalarial therapeutic, and 
helped spearhead a cascade of studies focused primarily on the biochemical characterization of the 
binding between the drug (or its variants) and its putative target [2–8] and potency optimization 
through the design of triclosan analogs [3, 9–14]. However, a study published in 2008 showed that a 
FabI mutant Pf line did not differ from its WT counterpart with respect to sensitivity to triclosan, thus 
indicating that the inhibition of ABS Pf growth by the drug is not achieved through the inhibition of 
FabI [15]. Moreover, the same study showed that FabI knock-out parasites (both Pb and Pf) were not 
affected in their ability to elongate FA compared to WT, thus indicating that all FA elongation is 
catalyzed by an elongation pathway (ELO) rather than by the FAS-II de novo FA synthesis pathway 
[15]. As evidenced by the attenuated infectivity of sporozoites derived from Pb parasites lacking FabI, 
the protein was found to be important for the development of ALS merozoites instead [15], consistent 
with microarray data showing that a significant number of genes and proteins of the FAS-II pathway 
are specifically expressed during the ALS [16]. Further complicating matters, authors of a Nature 
Correspondence from 2011 examined the 2001 study by Surolia and Surolia and reported that, while they 





effect in vivo [17]. Given such inconsistent findings among the various studies, it remains unclear as to 
what the actual drug targets of triclosan are in ABS malaria parasites. 
Recently, a study identified dihydrofolate reductase (DHFR) of both Pf and Pv to be a target 
of the antimalarial action of triclosan [18]. To arrive at this conclusion, the authors generated strains 
of Saccharomyces cerevisiae (Sc) in which the gene encoding the essential ScDHFR is replaced by that 
encoding either PfDHFR or PvDHFR, its ortholog in Pf and Pv, respectively [18–20]. Given that the 
deletion in Sc can be complemented by the presence of the Plasmodium ortholog, these mutant yeast 
strains enable one to screen for any drug that targets PfDHFR [18–20]. Using this strategy, Bilsland et 
al. (2018) identified DHFR as a target of the antimalarial action of triclosan in Pf as well as Pv, and 
subsequently confirmed this in vitro [18]. While this study has helped shed light on the antimalarial 
action of triclosan, it also raises two important points of consideration regarding triclosan. First, 
DHFR is a target of the antifolates pyrimethamine and proguanil. The former is used in combination 
with sulfadoxine in the drug sulfadoxine-pyrimethamine (SP, trade name Fansidar), which was 
introduced around 1970 and was quickly met with resistant strains (reviewed in [21]); similarly, the 
latter is used in combination with atovaquone in the drug atovaquone-proguanil (AP, trade name 
Malarone), which was introduced around 2000 and was likewise quickly met with resistant strains 
(reviewed in [21]). As such, if DHFR is the sole target through which triclosan exerts its antimalarial 
effect, then the pursuit of triclosan analogs as an antimalarial should perhaps be forsaken. That being 
said, however, previous studies have tested various triclosan analogs containing B-ring-only 
modifications against the Dd2 strain and observed notably improved potency compared to that of the 
parental compound [9, 15]. Now, since this particular Pf strain contains mutations within the dhfr gene 
that are known to confer resistance to pyrimethamine and proguanil (N51I, C59R, and S108N) [22] 
and is resistant to SP, such inhibitory effect of the analog against the Dd2 strain suggests that the drug 





consideration, the yeast screen employed by Bilsland et al. (2018) relies on the deliberate introduction 
of a candidate drug target gene from Plasmodium, or whatever other species of one’s choosing, into 
yeast. For this reason, the screen is more useful for one to confirm, but not discover, drug targets for 
which there is existing literature already supporting the role of the gene as a drug target. Because of 
this limitation as well, it is possible that there are additional primary targets of triclosan, other than 
DHFR, that remain to be identified. 
With all of this taken into consideration, we have taken a twofold approach with the goal of 
developing a novel potent triclosan-based antimalarial. First, we have screened a group of triclosan 
analogs against the growth of ABS Pf in vitro in order to identify the most potent compound among 
the group. Second, we seek to identify the specific drug targets of this analog within the parasite 
through the induction of drug resistance followed by genomic DNA sequencing. Importantly, this 
twofold approach enables the comprehensive identification of all drug targets of this analog, a piece 
of information that would be invaluable towards the potency optimization of this analog. 
Now, the analogs examined herein contain various modifications of specific substituents 
around the diaryl ether scaffold of triclosan, based on the design of two notable triclosan analogs 
examined in previous studies – C25 from [9] (Figure 3.1B) and 39b from [23] (Figure 3.1D). In 
particular, Stec et al. (2013) screened for antiparasitic activity against ABS Pf using a wide variety of 
triclosan analogs, among which the most potent was the one designated 39b, which yielded an IC50 of 
30 nM and 80 nM towards the D6 (CDC/Sierra Leone) and TM91C235 (WRAIR, Thailand) Pf strains, 
respectively [23]. Such remarkable activity makes this compound one of the most potent triclosan 
analogs reported to date, and thus, an excellent candidate for further potency optimization. Now, since 
the augmented activity of 39b is solely attributed to modifications of the A-ring, we sought to further 
optimize its potency through modifications of its B-ring. In that regard, among the various B-ring 2’ 





exhibited notable antiparasitic activity against ABS Pf, with an EC50 of 180 nM and 220 nM towards 
the 3D7 and Dd2 strains, respectively [9]. As such, our primary triclosan analog of interest, the 
compound designated djm-11-05 (Figure 3.1C), is comprised of the A-ring of 39b and the B-ring of 
C25. Using this compound as the basis, we have chemically synthesized six additional compounds, 
each of which contains a modified 2’ substituent on the A- and/or B-ring of djm-11-05. Using this set 
of seven triclosan analogs, we first screened for antiparasitic activity against ABS Pf in order to identify 
the compound exhibiting the most potent activity, which was then used for resistance induction 
towards the goal of drug target identification.  
 
Figure 3.1. The chemical structure of triclosan and three of its analogs. Shown are the chemical 
structure of (A) triclosan, (B) C25, a notable compound from [9], (C) djm-11-05, the primary 
compound of interest in our study, and (D) 39b, a notable compound from [23]. As indicated by the 
color-coding, djm-11-05 is a triclosan analog comprised of the A-ring of 39b (pink) and the B-ring of 
C25 (blue). Using triclosan as an example, the A-ring and B-ring are indicated, and the numbering of 





MATERIALS AND METHODS  
Preparation of chemicals  
Each chemically synthesized triclosan analog included 0, 1, or 2X trifluoroacetic acid (TFA) as 
counterions. For each compound, the chemical structure (not including TFA) was drawn in 
ChemDraw, and the pure molecular weight was determined via ChemDraw. The actual molecular 
weight was determined by adding the molecular weight for the appropriate amount of TFA to the 
pure molecular weight. Based on the actual molecular weight, each compound was dissolved in the 
appropriate amount of DMSO to yield a 50 mM working stock, which was used for the parasite growth 
inhibition assays.  
 
Generation of growth curves used for IC50 determination  
Growth curves used for IC50 determination were generated using a plate-based assay. Given that the 
sensitivity of the parasite to a particular drug may vary depending on the stage of its life cycle [1, 24, 
25], all drug experiments were performed using synchronized parasites, following the same time 
scheme (Table 3.1) – 6 hours post synchronization, the IC plate was prepared; 48 hours post IC plate 
preparation, the parasitemia was measured using flow cytometry. The following subsections detail 












Table 3.1. The overall plan (per IC plate) for the drug assays. This overall plan was used to 




Parasite culture maintenance  
For all drug experiments, the NF54attB strain of Pf (the NF54 strain in which the attB recombination 
site is inserted into the cg6 genomic locus of the parasite) [26] was used. The culture was maintained 
in CMA medium using the same method as that detailed under the MATERIALS AND 
METHODS section from CHAPTER 2, with the exception that the hematocrit of the culture was 
kept at 5% (instead of 1%). This increases the parasite yield from the isolation of schizont-stage 
parasites via magnetic purification.  
 
Magnetic purification  
The isolation of schizont-stage parasites from the mixed-stage culture was done using the standard 
method of magnetic purification [27]. Briefly, a 75 cm2 cell culture flask containing 2 mL of CMA 
medium and 200 µL of 50% hematocrit human blood was prepared and warmed to 37oC. A MACS 
LS column (Miltenyi BioTec, cat. #130-042-401) was inserted into a homemade magnet with a field 
strength of about 8,000 G. The column was washed with 400 µL of CMA medium, loaded with the 





the magnet, and schizont-stage parasites were eluted with 8 mL of CMA medium from the column 
into the pre-prepared flask, thus yielding a 10 mL schizont-stage culture at 1% hematocrit.  
 
Flow cytometry  
The measurement of parasitemia on day 2 of each experiment employed the same flow cytometry-
based method as that detailed under the MATERIALS AND METHODS section from 
CHAPTER 2, with two exceptions: (1) each well was seeded at 1% hematocrit (instead of 2% 
hematocrit), and thus, 2 µL (instead of 1 µL) of sample per well was used for SYBR Green staining, 
and (2) each plate was stained with SYBR Green for 10 minutes (instead of 30 minutes).  
 
Preparation of the IC plate  
As illustrated in the layout of the IC plate below (Figure 3.2), each IC plate contains four different 
types of wells – drug, vehicle control, death control, and uninfected control. To prepare each IC plate, 
a total of three 96-well plates were used – the IC plate itself, the drug plate, and the DMSO plate 
(Figure 3.3). The following subsections detail the preparation of each of the three plates.  
 
Preparation of the drug plate 
As shown in Figure 3.3, the drug, typically with a stock concentration of 50 mM, is deposited into 
the A12 well of the drug plate. Then, across row A, the amount of drug is diluted from well to well by 
100% DMSO, from A12 all the way down to A1. For each experiment, the specific dilution factor 
used for each well-to-well dilution was flexible and depended on two factors: (1) in general, we aimed 
to have a decent spread of drug concentrations – four wells for the “kill zone” (wells having drug 
concentrations that are sufficiently high to kill off all parasites), four wells for the “no-kill zone” (wells 





wells for the “transition zone” (wells having drug concentrations that lie somewhere between that of 
the no-kill zone and the kill zone, and would thus contain the IC50 value for the drug). The final 
resulting range of drug concentration typically spans about 4 – 5 logs; (2) for each of the compound 
tested within our study, the IC50 curve has been generated at least twice. In the case when the IC50 
value was available (either from our first trial of measurement or from prior studies), we have adjusted 
the well-to-well dilution factor such that the expected resulting IC50 value would end up somewhere 
in the middle of the transition zone. 
In order to prevent a buildup of error that would result from a consecutive eleven-step serial 
dilution across row A, we first prepared, for each of the three zones, the well with the highest drug 
concentration (A12, A8, and A4 for the kill zone, transition zone, and no-kill zone, respectively), and 
then prepared, for each zone, the remaining three wells via serial dilution from the respective well with 
the highest drug concentration. More specifically, we first prepared the A12 well, and used the content 
within A12 to create the A8 well, from which the A4 well was then prepared. Finally, row B simply 
consists of a 1:40 dilution of row A. To prepare row B, therefore, 5 µL of row A was mixed with 195 
µL of CMA medium.  
 
Preparation of the DMSO plate 
As shown in Figure 3.3, the DMSO plate was prepared in the exact same manner as the drug plate, 
with the exception that inhibitors were not included in any of the wells.  
 
Preparation of the IC plate 
The parasitemia for the culture was determined using Giemsa staining. Based on this parasitemia, we 
calculated the amount of culture content, 50% hematocrit blood, and CMA medium required for 





volume per well in a 96-well flat-bottom cell culture plate (Corning, cat. #3595). Each parasite-
containing well was seeded as calculated, with the exception that 10 µL of CMA medium was first 
omitted, thus giving an initial total volume of 240 µL per well; each uninfected control well (IC plate 
D10 – D12) was prepared in the same manner as a parasite-containing well, with the exception that 
there were no parasites added. After preparation of the 240 µL for each well, 10 µL of specific content, 
depending on the well, was added to each well as follows: (1) for rows A, B, and C of the IC plate, 10 
µL of drug plate row B was added. As illustrated in Figure 3.3, this addition constitutes a 1:25 dilution 
of both the drug and DMSO in drug plate row B, thus yielding a specific final drug concentration as 
well as 0.1% DMSO in CMA medium for each well; (2) for D1 – D6 (vehicle control) and D10 – D12 
(uninfected control) of the IC plate, 10 µL of DMSO plate row B was added. As illustrated in Figure 
3.3, this addition constitutes a 1:25 dilution of the DMSO in DMSO plate row B, thus yielding 0.1% 
DMSO in CMA medium for each of the nine wells; (3) the IC plate death control wells (D7 – D9) 
were prepared in the same fashion as the other drug wells, yielding 10 µM chloroquine in 0.1% DMSO 









Figure 3.2. Layout of the IC plate. Each IC plate contains four different types of wells – drug (blue), 
including one set for drug A and another set for drug B, vehicle control (yellow), death control (pink), 
and uninfected control (green). For drug A, triplicate wells were seeded, with replicate 1, 2, and 3 
occupying row A, B, and C, respectively; for drug B, triplicate wells were seeded, with replicate 1, 2, 
and 3 occupying row E, F, and G, respectively. Each well was seeded at 0.5% parasitemia (with the 
exception of the uninfected control wells, which contain no parasites), 1% hematocrit, 0.1% DMSO, 
and 250 µL total volume. Each drug well contains a specific concentration of a drug in 0.1% DMSO 
in CMA medium; each vehicle control well contains 0.1% DMSO in CMA; each death control well 
contains 10 µM chloroquine in 0.1% DMSO in CMA; each uninfected control well contains RBCs in 
0.1% DMSO in CMA.  
 
IC plate 
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 drug A 
B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 drug A 
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 drug A 
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 drug B 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 drug B 
G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 drug B 
H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12
Vehicle control (yellow):




Uninfected control (green): 
- 250 µL total vol.
- 0.1% DMSO 
- 1% hematocrit
Death control (pink): 
- 250 µL total vol.
- 0.1% DMSO 
- 1% hematocrit
- 0.5% parasitemia 
- 10 µM Chloroquine
Drug well (blue): 
- 250 µL total vol.
- 0.1% DMSO 
- 1% hematocrit
- 0.5% parasitemia






Figure 3.3. Preparation of the IC plate. Shown (from top to bottom) are the drug plate (rows A 
and B), IC plate (rows A to D), and DMSO plate (rows A and B). As indicated in this example IC 
plate preparation, drug plate A12 contains 50 mM drug, and the drug plate row A well-to-well dilution 
factor is indicated. The dilution scheme used to prepare drug plate column 12 is shown; the 
concentration of drug and DMSO for each well is indicated.  
 
Determination of IC50 values 
IC50 values were determined using the GraphPad Prism software (version 5.01). Briefly, for each well, 
the log [drug concentration (M)] (y-value) and the corresponding %parasitemia (x-value) were entered 
into the software. The data were analyzed with non-linear regression (curve fit) analysis, using the log 
[inhibitor] vs. response equation and the least squares (ordinary) fitting method.  
 
drug plate 
dilution factor: 3 3 3 3 2 2 2 3 3 3 3
1 2 3 4 5 6 7 8 9 10 11 12
row A 0.001 0.003 0.009 0.026 0.077 0.154 0.309 0.617 1.852 5.556 16.667 50.000 mM drug
1.0 2.9 8.6 25.7 77.2 154.3 308.6 617.3 1851.9 5555.6 16666.7 50000.0 µM drug 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% DMSO 
row B
0.02 0.07 0.21 0.64 1.93 3.86 7.72 15.43 46.30 138.89 416.67 1250.00 µM drug 
2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% DMSO 
IC plate 
1 2 3 4 5 6 7 8 9 10 11 12
row A 1.0 2.9 8.6 25.7 77.2 154.3 308.6 617.3 1851.9 5555.6 16666.7 50000.0 nM drug
0.001 0.003 0.009 0.026 0.077 0.154 0.309 0.617 1.852 5.556 16.667 50.000 µM drug 




0 0 0 0 0 0 0 0 0 µM drug 
0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% DMSO 
D MSO plate 
1 2 3 4 5 6 7 8 9 10 11 12
row A
0 0 0 0 0 0 0 0 0 0 0 0 µM drug 
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% DMSO 
row B
0 0 0 0 0 0 0 0 0 0 0 0 µM drug 










RESULTS AND DISCUSSION  
Validation of the drug assay  
Our drug assay was validated by testing various drugs for which the IC50 value is already known based 
on previous studies – atovaquone, triclosan, and djm-11-03A, the same compound as 39b from [23]. 
The IC50 for atovaquone against Pf has been determined to be ~1 nM [28], and we have been able to 
reproduce this result consistently under our experimental conditions (Figure 3.4A). The IC50 for 
triclosan against Pf has been determined to be in the micro-molar range [1, 9], consistent with our 
measurements (Figure 3.4B and Table 3.2). As mentioned in the INTRODUCTION section of 
this chapter, the IC50 for 39b from the study by Stec et al. (2013) was determined to be 30 nM and 80 
nM towards the D6 and TM91C235 Pf strains, respectively [23]. Although our assays were done using 
the NF54attB strain of Pf, the IC50 value for djm-11-03A was consistently determined to be in the same 
range (Figure 3.4G and Table 3.2).  
 
Structure—activity relationship based on six triclosan analogs 
The schematic illustrating the relationship between chemical structure and antiparasitic activity for six 
triclosan analogs is given below (Figure 3.5). Three notable observations can be made based on this 
schematic: (1) among these six triclosan analogs, djm-11-03A exhibited the strongest antiparasitic 
activity against ABS Pf, with an IC50 of 33 – 44 nM; (2) by comparing djm-10-25 to djm-10-44, a 2’ 
amine, rather than a 2’ chlorine, on the B-ring seems to work better with the 2’ methoxy group on the 
A-ring; (3) by comparing djm-11-03A to either djm-10-25 or djm-11-05, the 2’ hydroxyl and the 2’ 







Figure 3.4. IC50 curves for various antimalarial drugs. Shown are the IC50 curves for (A) 
atovaquone, (B) triclosan, and six triclosan analogs – (C) djm-10-25, (D) djm-10-30, (E) djm-10-44, 
(F) djm-10-85, (G) djm-11-03A, and (H) djm-11-05. 6 hours post synchronization, NF54attB Pf 
parasites were seeded at 0.5% parasitemia, and allowed to grow for 48 hours in the presence or absence 
of a drug (see the MATERIALS AND METHODS section for details). The determined IC50 and 
95% CI are indicated below each graph. Each data point (error bar) represents the mean (standard 
djm-10-25





















• IC50: 2,300 nM
• 95% CI: 1,100 – 4,900 nM 
djm-10-44



















• IC50: 690 nM 
• 95% CI: 350 – 1,400 nM 
Atovaquone



















• IC50: 1.0 nM
• 95% CI: 0.66 – 1.2 nM 
djm-11-03A





















• IC50: 44 nM
• 95% CI: 31 – 61 nM 
djm-10-85




















• IC50: 2,000 nM 
• 95% CI: 1,200 – 3,500 nM 
Triclosan




















• IC50: 3,000 nM
• 95% CI: 1,900 – 4,700 nM 
djm-11-05




















• IC50: 330 nM
• 95% CI: 150 – 690 nM 
djm-10-30






















• IC50: 1,500 nM 








deviation) derived from four technical replicates. For any data point, the apparent absence of an error 
bar is due to its small size. The IC50 curves for each drug was measured at least twice, and the curves 
shown are representative of each drug.  
 
Table 3.2. General information on triclosan and seven of its analogs. Shown below are the name, 
exact mass (i.e., pure molecular weight), chemical structure, IC50, and 95% CI for triclosan and seven 
of its analogs. With the exception of djm-10-56, which exhibited poor inhibitory activity against the 
growth of ABS Pf, values for IC50 and 95% CI from two biological replicates are shown for each drug. 
The average IC50 value is indicated in red. All numeric values for IC50 and 95% CI are shown with two 
significant digits.  
Compound  Exact mass 
(g/mol) 






2,300 – 4,900  
1,900 – 4,700 
 



















430 – 11,000 











1,000 – 2,300  







130 – 590  







1,200 – 3,500  
2,200 – 6,300 






18 – 60  
31 – 61 






330 – 830  
150 – 690  









Figure 3.5. Structure—activity relationship based on six triclosan analogs. A schematic 
illustrating the relationship between chemical structure and antiparasitic activity for six triclosan 
analogs is depicted. For each compound, the average IC50 value (in nM) is indicated in red, and these 







Herein, we have examined seven triclosan analogs vis-à-vis their antiparasitic activity against ABS Pf. 
Among these analogs, djm-11-03A exhibited the strongest activity, with an average IC50 of 39 nM. 
Moreover, examination of the structure—activity relationship based on six of these analogs indicates 
that the outstanding activity of djm-11-03A could be attributed, at least in part, to the synergistic effect 
between its A-ring 2’ hydroxyl and its B-ring 2’ chlorine. However, as we were not able to improve 
the potency of this preexistent compound, future experiments may involve the screening for 
antiparasitic activity using additional novel triclosan analogs. Importantly, given that djm-11-03A 
exhibited excellent potency against ABS Pf, we have opted to carry out drug resistance induction 
experiments with this compound. Once resistant parasites are obtained, we plan to carry out genomic 
sequencing in order to uncover the genetic determinants of drug resistance. In particular, a clear 
answer may come in the form of either a mutation in a candidate drug target gene or a copy number 
variation for that gene. In any case, the results from the genomic sequencing should be confirmed by 
the mutation, knock-down, or over-expression of the candidate gene. All in all, such an approach 
should help uncover the specific drug targets of this compound, and thus, shed light on how to further 
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CHAPTER 4: PyrKII and apicoplast maintenance  
ABSTRACT  
Pf harbors two isoforms of Pyruvate Kinase – PyrKI and PyrKII, which are localized to the cytosol 
and the apicoplast, respectively. While it has been shown that PyrKII is essential for the maintenance 
of the apicoplast, reasons for this requirement are yet to be determined. Within the apicoplast, PyrKII 
is thought to catalyze the conversion of PEP and ADP into pyruvate and ATP. Pyruvate can then 
either be converted into acetyl CoA, the precursor of the FAS-II pathway, or fed directly into the 
MEP pathway to generate isoprenoids. Using PfMev-based genetic knock-outs of various enzymes of 
the MEP pathway, we have empirically demonstrated that the MEP pathway, while essential to parasite 
survival during the ABS, is not required for maintaining the apicoplast. Furthermore, previous studies 
have shown that the deletion of certain components of the FAS-II pathway yielded no growth defect 
in the ABS. Taken together, these results indicate that maintenance of the apicoplast by PyrKII does 
not occur due to its pyruvate generation function. The alternative explanation, then, is that its ATP 
generation function is somehow required for maintaining the organelle. Given this, we have taken a 
twofold approach to help address the question – (1) we are testing the substrate specificity of various 
(d)NTPs against PyrKII in vitro, and (2) we aim to carry out a microarray analysis in order to examine 
the changes within the nuclear and apicoplast transcriptome in response to knocking down PyrKII 
during the ABS. Towards the second goal, we are testing two different knock-down methods. The 
first is a Tet-on system called the TetR-DOZI system and the second is a conditional localization 
system (CLD) that diverts PyrKII from the apicoplast and causes the protein to be secreted. Herein, 
we demonstrate the capability of the TetR-DOZI system and the CLD system to conditionally knock 








PyrKII in Plasmodium spp.  
Pf and the related apicomplexan parasite Tg both harbor two isoforms of PyrK – PyrKI and PyrKII. 
TgPyrKI localizes to the cytosol, while TgPyrKII localizes to both the mitochondrion and the 
apicoplast [1]. PfPyrKII, unlike PfPyrKI, contains a putative N-terminal apicoplast-targeting bipartite 
pre-sequence [2], and exclusively localizes to the apicoplast [3]. This exclusive localization, coupled 
with the fact that PyrKII is actively transcribed during the ABS [2], suggests that the protein likely 
carries out a function that is essential for the organelle. As shown in the putative metabolic pathways 
involving PfPyrKII (Figure 4.1), cytosolic phosphoenolpyruvate (PEP) must first traverse the four 
membranes of the apicoplast in order to reach the apicoplast-localized PyrKII. This translocation is 
thought to be accomplished through the outer triose phosphate transporter (oTPT) and the inner 
triose phosphate transporter (iTPT), which are located across the outermost and innermost 
membranes, respectively, of the apicoplast [4]. Using PEP and ADP as substrates, PyrKII is thought 
to catalyze the generation of pyruvate and ATP. The resulting pyruvate can then serve as the starting 
material for either the MEP pathway or the FAS-II pathway. 
Using PfMev as the parental line, we have generated ΔPyrKII parasites, and demonstrated, via 
a combination of fluorescence microscopy and organellar genome PCR, that PyrKII is required for 
the maintenance of the apicoplast. As shown in the RESULTS AND DISCUSSION section of 
CHAPTER 2, the MEP pathway, although essential for the survival of ABS Pf, is not required for 
maintaining the apicoplast itself. Furthermore, no growth defect in the ABS was observed upon 
knocking out certain components of either the PDH complex [5] or particular enzymes of the FAS-
II pathway [6, 7]. Taken together, these results suggest that the generation of pyruvate by PyrKII is 
dispensable with respect to the maintenance of the apicoplast, which led to our hypothesis that the 





results from our lab have demonstrated that pure recombinant PyrKII exhibits catalytic activity against 
all NDPs and dNDPs in vitro, with the strongest activity against the purines ADP and GDP. While 
this indicates a lack of specificity for any single NDP substrate, we reasoned that a loss of various 
NTPs could inhibit certain apicoplast enzymes and functions, including translation (GTP) and 
transcription (all NTPs). Based on the hypothesis that transcription could be affected, we sought to 
compare the nuclear and apicoplast transcript levels upon knocking down PyrKII. To that end, we 
have applied the CLD system and the TetR-DOZI system [8] to our PfMev line to generate the PyrKII 
CLD and PyrKII TetR-DOZI lines, respectively. The results presented in this chapter demonstrate 
the capability of both systems to conditionally knock down PyrKII.  
 
 
Figure 4.1. Putative metabolic pathways involving PyrKII in the Plasmodium apicoplast. In 
exchange for exporting an inorganic phosphate, PEP is imported into the apicoplast through the 
oTPT and iTPT. PyrKII catalyzes the conversion of ADP and PEP into pyruvate and ATP. Pyruvate 
can then undergo one of two fates: (1) it can be converted by the PDH complex into acetyl CoA, 
which is then fed into the FAS-II pathway to synthesize fatty acids, or (2) it can be directly fed into 







The CLD system for conditionally knocking down PyrKII 
The design for the CLD system employed herein to conditionally knock down PyrKII was derived 
from a preexisting molecular tool for studying malaria parasites – the destabilization domain (DD) 
system. To implement the latter system, a mutated version of Homo sapiens (Hs) FK506 binding protein 
(FKBP) is fused to a protein of interest and serves as the so-called DD. Modulation of the protein 
level is achieved through the addition of Shield1, a synthetic cell-permeable ligand to which the DD 
binds. More specifically, when Shield1 is provided in the growth medium, it binds to the DD, 
stabilizing its structure and thus preventing degradation of the fusion protein. Under permissive 
conditions, however, the DD remains unstructured, and consequently targets the fusion protein for 
degradation by the proteasome of the parasite. Since the DD system relies on the cytosolic proteasome, 
it does not work well for organellar proteins. Nonetheless, for cytosolic proteins, the DD system has 
been shown to be capable of conditionally knocking down the expression of both episomally 
expressed [9] and endogenous [10–12] proteins in Pf. Given this, we adapted the DD system as a 
conditional localization system (see below) for the conditional knock-down of PyrKII in the parasite. 
The CLD system relies on the N-terminal modification of a protein of interest to control its 
localization. In the phylum Apicomplexa, trafficking of a nuclear-encoded protein to the apicoplast is 
a two-step process that requires the presence, on the N-terminus of the protein, of a bipartite pre-
sequence comprised of two domains – the signal peptide and the transit peptide [13] (Figure 4.2A). 
First, the signal peptide mediates co-translational import of the protein into the secretory pathway, i.e., 
the endoplasmic reticulum (ER). At some point during this process, perhaps shortly after import into 
the rough ER, the signal peptide gets cleaved off by the signal peptide peptidase (SgPP) [14]. The 
revealed transit peptide is thought to then mediate transfer of the protein into the lumen of the 
apicoplast [13]. Upon arrival at the apicoplast, the transit peptide is thought to be cleaved off by the 





4.2A). To generate the PyrKII CLD line, we genetically modified the natural bipartite pre-sequence 
of PyrKII – the original signal peptide was replaced with that of the acyl carrier protein (ACP), a 
nuclear-encoded apicoplast-localized protein [13, 15, 16] that functions in the FAS-II pathway, while 
the original transit peptide was replaced with what we named the CLD (Figure 4.2B). For the choice 
of CLD, we selected a variant of Hs FKBP containing specific mutations that enhance its binding with 
Shield1 [9]. We mutated this protein to introduce positively charged amino acid residues that are 
required for apicoplast transport. In addition, we introduced mutations that partially destabilize the 
FKBP domain so that the binding of Shield1 stabilizes the structure of the CLD. Importantly, a lack 
of transit peptide structure is required for the trafficking of proteins from the secretory pathway to 
the apicoplast, while the formation of structure in the transit peptide blocks apicoplast import [17]. 
Given this, the ability to control the structure of the CLD via the addition of Shield1 affords a 
molecular tool allowing the ligand-tunable mislocalization of a protein of interest. In particular, under 
permissive conditions (Figure 4.2B), the signal peptideACP directs the protein to the ER. After cleavage 
of the signal peptideACP, the exposed CLD, with an unstable structure, directs the tagged protein to 
the apicoplast. By contrast, when Shield1 is provided in the growth medium (Figure 4.2C), the ligand 
binds to the CLD, stabilizing its structure and thereby causing the tagged protein to be secreted from 








Figure 4.2. PyrKII translocation for normal Pf vs. the PyrKII CLD line. (A) Normal Pf. The 
signal peptide directs the protein to the secretory pathway, where the signal peptide gets cleaved off 
by the SgPP. The exposed transit peptide then directs the protein to the apicoplast, where the transit 
peptide gets cleaved off by the SPP, revealing the functional mature protein. (B) No Shield1 is 
provided in the growth medium for PyrKII CLD. The signal peptideACP directs the protein to the 
secretory pathway, where the signal peptideACP gets cleaved off. The exposed CLD then directs the 
protein to the apicoplast, where the CLD gets cleaved off by the SPP, revealing the functional mature 
protein. (C) Shield1 is provided in the growth medium for PyrKII CLD. The signal peptideACP directs 
the protein to the secretory pathway, where the signal peptideACP gets cleaved off. Shield1 binds to the 
CLD, stabilizing the structure of the CLD, and causing the tagged protein to be secreted from the 





The TetR-DOZI system for conditionally knocking down PyrKII  
Similar to the CLD system, the TetR-DOZI system also relies on the addition of a small molecule to 
conditionally modulate the expression of a protein of interest. The TetR-DOZI system was derived 
from its primitive variant, the TetR system. Under the latter system, Tet repressor protein (TetR)-
binding RNA elements, or aptamers in short, are genetically encoded into the 5’ untranslated region 
(5’ UTR) of the mRNA of a protein of interest [18, 19]. These aptamer regions form stem loop 
structures, in the mRNA, to which TetR specifically binds [19]. Under this setup, therefore, 
exogenously introduced TetR binds to these aptamer regions, thereby inhibiting the translation of the 
open reading frame [8, 18, 19]. However, when tetracycline analogs such as anhydrotetracycline (aTc) 
and doxycycline (Dox) are provided, these small molecules bind to TetR, preventing the binding of 
TetR to the aptamer regions, and thus allowing translation to occur normally [8, 18, 19]. Initially, the 
capability of the system to control the expression of exogenously introduced reporter proteins was 
demonstrated in yeast [19]. However, when the system was implemented in Pf to successfully control 
the expression of both reporter and endogenous proteins, only aTc was used as the chemical inducer 
of translation [18], presumably to avoid the use of Dox, which possesses specific antimalarial 
properties [20]. 
Now, the TetR-DOZI system was optimized from its predecessor through two major changes: 
(1) the aptamer regions are genetically encoded within the 3’ UTR (instead of the 5’ UTR) of the 
mRNA of the protein of interest, and (2) a TetR-DOZI fusion protein (instead of TetR alone) is 
employed to achieve translational repression [8]. DOZI (development of zygote inhibited), an RNA 
helicase that belongs to the DDX6 family of RNA helicases, has been implicated in the translational 
repression of select mRNA transcripts in Pb, and its loss in female Pb gametocytes has been 
phenotypically linked to a failure of fertilized female gametes (zygotes) to develop normally [21]. In 





protein synthesis, Dhh1p targets the transcript for de-capping and degradation [22]. Being the Pf 
homologue of Dhh1p and having a role in translational repression in Pb, DOZI made for an apt choice 
as a TetR fusion protein for the enhancement of translational inhibition in Pf. Importantly, in Pf, the 
noted changes from the original TetR system have been shown to not only significantly (by nearly 
fourfold) enhance the aTc-inducible regulation of gene expression but also reduce leaky expression 
associated with the synthetic system [8]. 
Given the capability of the TetR-DOZI system to robustly and conditionally regulate gene 
expression in Pf, we have employed the system to knock down PyrKII, the protein of interest for our 
study. As depicted in the simplified schematic of our application of this system (Figure 4.3A), a 3’ 
UTR containing aptamer regions along with a transgene encoding the TetR-DOZI fusion protein was 
site-specifically integrated at the 3’ end of the PyrKII coding sequence. When no aTc is provided in 
the growth medium of the parasite (Figure 4.3C), TetR of the fusion protein binds to the aptamer 
regions within the 3’ UTR, thereby leading to the translational inhibition of the mRNA transcript. On 
the other hand, when aTc is provided in the growth medium (Figure 4.3B), the molecule binds to 
TetR, preventing the binding of the fusion protein to the aptamer regions and thus allowing translation 








Figure 4.3. Conditional knock-down of PyrKII via the TetR-DOZI system. (A) A simplified 
schematic of our application of the TetR-DOZI system to conditionally knock down Pf PyrKII. A 
double-stranded cut is introduced at the 3’ end of the PyrKII gene, followed by integration of the 
linear plasmid into the cut site. (B) When aTc is provided in the growth medium, the molecule binds 
to TetR of the TetR-DOZI fusion protein, preventing the binding of TetR to the aptamer region 
within the 3’ UTR, thus allowing translation of the PyrKII mRNA. (C) When no aTc is provided in 
the growth medium, the TetR-DOZI fusion protein binds to the aptamer region within the 3’ UTR, 
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MATERIALS AND METHODS  
Generation of growth curves  
Growth curves were generated using a plate-based SYBR Green assay. As illustrated in the overall 
plan (per IC plate) used to generate growth curves for the PyrKII TetR-DOZI and PyrKII CLD 
parasite lines (Table 4.1), the IC plate was prepared 6 hours post synchronization. The parasites were 
allowed to grow up to day 4, at which time the parasitemia was cut by a factor of 10 to generate a cut 
IC plate in addition to the original uncut IC plate. The uncut version was allowed to grow for two 
additional days (up to day 6), while the cut version was allowed to grow for four additional days (up 
to day 8). For each curve, the parasitemia was measured using flow cytometry every other day, starting 
from day 0. This is different from the overall plan (per IC plate) given in CHAPTER 2, and is 
explained in the RESULTS AND DISCUSSION section of this chapter. The following subsections 
detail each step of the overall plan. 
 
Table 4.1. The overall plan (per IC plate) for growth curve generation for the PyrKII lines. 
This plan was used for both the PyrKII TetR-DOZI and PyrKII CLD parasite lines.  
 
 
Parasite culture maintenance  
The culture was maintained using the same method as that detailed under the MATERIALS AND 





the PyrKII TetR-DOZI line was maintained on CMA medium supplemented with 0.5 µM aTc (Sigma-
Aldrich, cat. #37919). 
 
Magnetic purification  
The isolation of schizont-stage iRBCs from the mixed-stage culture employed the same method as 
that detailed under the MATERIALS AND METHODS section from CHAPTER 3, with the 
exception that, for the PyrKII TetR-DOZI line, CMA medium supplemented with 0.5 µM aTc was 
used.  
 
Flow cytometry  
The measurement of parasitemia employed the same flow cytometry-based method as that detailed 
under the MATERIALS AND METHODS section from CHAPTER 2, with the exception that 
the parasitemia was measured every other day. On each day of measurement, the measured samples 
included those that were collected on the day of measurement in addition to the CR plate samples that 
were collected from the previous day.  
 
Sample collection and storage  
The cold room (CR) storage conditions are the same as that detailed under the MATERIALS AND 










RESULTS AND DISCUSSION  
Shield1 toxicity test  
We have generated a PfMev-based ΔPyrKII line, and used a combination of organellar genome PCR 
and fluorescence microscopy to show that PyrKII is required for the maintenance of the apicoplast 
(data not shown), and thus the survival of ABS Pf. As mentioned in the INTRODUCTION section 
of this chapter, the addition of Shield1 to the PyrKII CLD line will result in the secretion of PyrKII 
from the parasite. Because of this, the knock down of PyrKII expression via the CLD system should 
result in a noticeable decrease in the parasitemia. Now, although one study has shown that the 
treatment of Pf with Shield1 at 500 nM for 48 h (i.e., spanning the entire first parasite life cycle) led to 
an 11% decrease in parasitemia [10], another study noted that treatment with the same concentration 
for 3 days did not inhibit parasite growth [9]. Regardless, we reasoned that it was imperative to first 
carry out a toxicity test in order to determine the maximum concentration of Shield1 at which no 
toxicity is elicited by the presence of the ligand itself. Presumably, this concentration would allow the 
maximum downregulation of protein expression while avoiding any potential inherent toxicity 
associated with the ligand. To that end, we used the PfMev parasite line for this test since it is the 
parent of the PyrKII CLD line. As for the concentration, we chose to test 0, 25, 100, and 500 nM. As 
evident from the resulting growth curve (Figure 4.4), there is an apparent decrease in growth for the 
500 nM condition in comparison to the other three conditions, indicating that Shield1 at 500 nM 
might be slightly toxic. However, examination of the raw data shows that the precise mean ± SD 
starting parasitemia for the 0, 25, 100, and 500 nM Shield1 conditions were 0.47 ± 0.04%, 0.42 ± 
0.06%, 0.45 ± 0.09%, and 0.40 ± 0.07%, respectively. Thus, given that the seeded parasitemia of the 
500 nM condition is somewhat lower than of the other three media conditions, the apparent lower 
parasitemia for the 500 nM condition could be attributed, at least in part, to the lower starting 





over the span of 7 days (the approximate duration of our growth curve experiment), this concentration 
of the ligand was used for subsequent experiments for the PyrKII CLD line.  
 
Figure 4.4. Shield1 toxicity test. Non-synchronous PfMev parasites were seeded on day 0 at ~0.5% 
parasitemia and allowed to grow up to day 4, at which time the parasitemia was cut down by a factor 
of 10. Thereafter, the parasites were allowed to grow up to day 7. As indicated, four different media 
conditions were used – CMA medium with 0, 25, 100, or 500 nM Shield1. Each data point (error bar) 
represents the mean (standard deviation) derived from four technical replicates. For any data point, 
the apparent absence of an error bar is due to its small size. 
 
Optimization of the flow assay for the detection of synchronous parasites  
Following the time scheme detailed under the MATERIALS AND METHODS section, the even-
days (days 2, 4, 6, and 8) correspond to the late-stages of the parasite life cycle (Table 4.1). As we have 
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consistently observed under this time scheme, storage of parasite samples under 4oC and measuring 
the samples one or more days later yields an apparent dip in the parasitemia exclusively for the even-
day samples (data not shown). On the other hand, measuring the parasitemia of the even-day samples 
on the day of sample collection eliminates the apparent dip (Figure 4.4 and Figure 4.5). Our 
hypothesis for this phenomenon is that late-stage parasites either break down or release immature 
merozoites if left for one or more day period at 4oC. In particular, an examination of the flow 
cytometer gates (data not shown) revealed the presence, for the even-day samples exclusively, of a 
congregated group of SYBR Green-positive objects lying outside the R1 gate. The atypical scattering 
profile of these objects and the fact that they are SYBR Green-positive indicate that these objects are 
probably free merozoites. Furthermore, the invasion of RBCs by free merozoites is a complex process 
involving a slew of specific interactions between select parasitic and RBC surface proteins (reviewed 
in [23]), and it is possible that some of these proteins, of the RBC and/or the parasite, are only 
functional under a specific temperature range. Since the cytometer gates are set up to detect SYBR 
Green fluorescence that is derived exclusively from objects the size of RBCs (Figure 2.5), objects the 
size of merozoites, albeit SYBR Green-positive, would be excluded from the count, thus leading to 
an apparent dip in the parasitemia. Therefore, for all growth curve experiments involving synchronous 
parasites, the samples were analyzed every other day starting from day 0, following the time scheme 
given in Table 4.1. This method not only eliminates the problem with storing late-stage parasites for 
extended periods of time but also avoids the need to add additional steps and fixative reagents to 
preserve the cells. 
 
The CLD system conditionally knocks down the expression of PyrKII  
Synchronous early ring-stage PyrKII CLD parasites were seeded at 0.5% parasitemia on day 0 and 





curves, three observations can be made regarding the conditional knock-down of PyrKII via the CLD 
system. (1) As expected, the addition of Shield1 to the growth medium led to a decrease in parasitemia 
compared to the other three media conditions (Figure 4.5, blue vs. yellow, red, and green), indicating 
that the expression of PyrKII is being knocked down via the CLD system; (2) starting from the early 
ring-stage of the first life cycle (day 0, 6:00 P.M.), the effect of the CLD system is observable starting 
from the beginning of the second life cycle (day 3, ~12:00 P.M.), indicating that the effect of the CLD 
system manifests in a phenotypically visible manner at some time point between day 2 and day 3; and 
(3) past day 2, Mevalonate supplementation only enables a partial restoration of growth, as evidenced 
by a parasitemia lying between that of the no-kill conditions (Figure 4.5, yellow and red) and that of 
the kill condition (Figure 4.5, blue).  
 
Figure 4.5. Growth curves for PyrKII CLD. On day 0, 6 hours post synchronization, the parasites 
were seeded at 0.5% parasitemia and either (A) allowed to grow up to day 6 without any cut down, or 
(B) cut down by a factor of 10 on day 4 and then allowed to grow up to day 8. Four different media 
conditions were used as indicated. Mevalonate was used at 50 µM, while Shield1 was used at 500 nM. 
Each data point (error bar) represents the mean (standard deviation) derived from four technical 
replicates. For any data point, the apparent absence of an error bar is due to its small size.  
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Figure 4.6. Growth curves for PyrKII TetR-DOZI. On day 0, 6 hours post synchronization, the 
parasites were seeded at 0.5% parasitemia and either (A) allowed to grow up to day 6 without any cut 
down, or (B) cut down by a factor of 10 on day 4 and then allowed to grow up to day 8. Four different 
media conditions were used as indicated. Mevalonate was used at 50 µM, while aTc was used at 0.5 
µM. Each data point (error bar) represents the mean (standard deviation) derived from four technical 
replicates. For any data point, the apparent absence of an error bar is due to its small size.  
 
The TetR-DOZI system conditionally knocks down the expression of PyrKII  
As with the CLD system, synchronous early ring-stage PyrKII TetR-DOZI parasites were seeded at 
0.5% parasitemia on day 0 and allowed to grow under one of four media conditions (Figure 4.6). 
Based on the resulting growth curves, three observations can be made regarding the conditional 
knock-down of PyrKII via the TetR-DOZI system. (1) As expected, the absence of aTc in the growth 
medium led to a decrease in parasitemia compared to the other three media conditions (Figure 4.6, 
yellow vs. red, blue, and green), indicating that the expression of PyrKII is being knocked down via 
the TetR-DOZI system; (2) starting from the early ring-stage of the first life cycle (day 0, 6:00 P.M.), 
the effect of the TetR-DOZI system is observable starting from the middle of the third life cycle (day 
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5, ~12:00 P.M.). Importantly, this timing has been consistently observed for the PyrKII TetR-DOZI 
line, and indicates that the effect of the system manifests in a phenotypically visible manner at some 
time point between day 4 and day 5; and (3) past day 6, Mevalonate supplementation only enables a 
partial restoration of growth (Figure 4.6B), as evidenced by a parasitemia lying between that of the 
no-kill conditions (Figure 4.6B, blue and green) and that of the kill condition (Figure 4.6B, yellow).  
 
Comparison of the CLD system and the TetR-DOZI system 
Two key observations can be made when the two conditional knock-down systems are compared. (1) 
For both parasite lines, the Mevalonate bypass system is only able to partially restore the growth of 
the parasites. Although this has been consistently observed for both lines, reasons for this are only a 
subject of speculation. Since the Mevalonate bypass condition allows PyrKII knock-out parasites to 
grow normally, it should work equally well for the knock-down lines. However, normal growth may 
require an adaptation period and we are still observing the transition to Mevalonate-dependence in 
our experiments. (2) Compared to the TetR-DOZI system, the CLD system seems to be more robust 
in that the growth phenotype on day 3 is more pronounced for the CLD system, at least under the 














The results presented in this chapter demonstrate that both the CLD system and the TetR-DOZI 
system are capable of conditionally knocking down PyrKII, our protein of interest for this study. 
Importantly, these systems allow us to scrutinize, using microarray analysis, the transcriptional changes 
within the nuclear as well as apicoplast genome that result from the knock-down of this essential 
protein. Based on such data, we hope to observe a disruption and loss of apicoplast gene transcription 
prior to any loss of nuclear gene expression. Those results will help shed light on why PyrKII is so 
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